2006 drugs estimate refuels debate on governance. by Pike, Brigid
The National Documentation
Centre on Drug Use has moved to
new, larger premises on Lower
Mount Street in Dublin. The NDC,
along with the Drug Misuse
Research Division and a number of
other divisions of the Health
Research Board, took up residence
in Knockmaun House at the end of
February. The move comes just over
three years after the NDC first
opened in Holles Street. This is an
exciting development for the NDC
as it allows room for expansion
both of the library’s collections and
of the range of services it provides.
The new library will continue to
provide an information service to
visitors and anyone can drop in to
discuss their research interests or
information needs with NDC staff.
See p. 22 for more information
on the NDC and new contact
details.
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Drugnet Ireland readers survey
This is your opportunity to tell us what you think of Drugnet Ireland and to let us
know whether there are any changes you would like to see in its content, format
or presentation. We will use the information gained through this survey to develop
the newsletter in response to your needs.
Inside this issue you will find a questionnaire and a pre-paid addressed envelope
which you can use to return the completed questionnaire to us. We know that you
are very busy, so we have designed the questionnaire to enable you to give us the
information we need in as short a time as possible. 
So, please take five minutes of your time to fill in the questionnaire and help us
make Drugnet Ireland an even better source of information on all drug-related
topics.
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The second
publication in the
Drug Misuse
Research Division’s
Overview series
was published in
December 2005.
The purpose of
this Overview, The
illicit drug market in
Ireland,1 was to
compile and
analyse existing
data and available
research on the
drug market, to
identify gaps in knowledge and to inform future
research needs in this important area of drug policy.
The illicit drug market can be understood as
incorporating three inter-related levels or
dimensions. The global or ‘international market’
incorporates drug production and international
trafficking; the ‘middle market’ involves the
importation and distribution of drugs at a national
level; and the ‘local market’ involves distribution at
a retail level.
Understanding the scale, nature and dynamics of
the drug market is a critical requirement for
effective policy-making and action. It is important
to understand the global interconnectedness of the
drug market as this has implications for
international relations. Also, by mapping out
‘middle market’ levels, research studies have
investigated how drugs are moved from
importation to street level, by whom and for what
profit. In doing so, such studies have identified
more efficient ways in which drug supply can be
disrupted. With regard to the ‘local market’, low-
level distribution networks are the principal means
by which drugs become available in a
neighbourhood. The ease of access to drugs is
regarded as an important determinant of
experimental drug use among adolescents. Local
drug markets can also instil fear and insecurity in
local communities. Consequently, there is a need to
identify and disrupt local drug sources and supply
routes. Knowledge of these networks, their
dynamics and their impact is an important
prerequisite for effective interventions, such as local
policing, harm reduction or housing initiatives.
Information and research on the illicit drugs
market in Ireland is extremely limited. In the case
of the importation and internal distribution of
drugs in Ireland, information is gathered by law
enforcement agencies such as Customs Drug Law
Enforcement and the Garda National Drugs Unit
(GNDU). When drugs are seized, Irish law
enforcement personnel seek to determine the
destination of the drugs by considering a number
of factors associated with the particular seizure: the
size of the seizure, the geographical location of the
seizure, whether, for example, weather conditions
inadvertently caused a diversion into Irish waters of
a particular shipment, and the circumstances of
the individuals apprehended along with the drugs.
Another possible indicator of national distribution
patterns is drug-related prosecutions by drug type
and by Garda division, which are reported in the
annual reports of An Garda Síochána. 
A number of localised studies have provided
further information on aspects of retail drug
markets and their impact on specific locations.
Such studies illustrate that the drug phenomenon
impacts disproportionately on the quality of life of
certain communities in Ireland, with drug-related
crime, nuisance and fear associated with such
markets of particular concern. Typically, such
communities already experience a range of other
social and economic problems such as poverty,
high levels of unemployment, educational
disadvantage and political marginalisation. Street-
level drug markets in such areas can add to the
sense of alienation often experienced by residents
and this in turn can operate as a disincentive to
engaging in community-based and inter-agency
policy responses. 
Drug price data enable us to estimate the value of
the illicit drug market. Knowledge of the value of
the illicit drugs market can provide an indication as
to its relative importance vis-à-vis local economies.
Price estimates obtained from the GNDU and from
a drug users’ support organisation, the Union for
Improved Services, Communication and Education,
were used to ascertain drug prices for the year
2003 as shown in the Overview. As the Irish illicit
drugs market is closely connected to that of the
UK and Northern Ireland, Irish drug prices were
compared with drug prices in these jurisdictions.
Systematic purity-testing of drugs seized at all
market levels can provide useful information on
market dynamics and profit margins.
The Overview provides information on drug
seizures, estimated illicit market value, drug
sources and trafficking patterns, drug prosecutions
by Garda region and drug availability. Among the
key findings were:
■ The total number of drug seizures reported in
the annual reports of the Garda Síochána
decreased by 17.2% between 2000 and
2003. The total number of seizures increased
from 5,603 in 2002 to 6,377 in 2003.
■ An upward trend in cocaine seizures in recent
years is evident. The number of cocaine
seizures increased steadily, from 42 seizures in
1995 to 566 in 2003, a growth of more than
1,200%. Since 2000, the quantity of cocaine
seized has increased by just less than 500%. A
small number of crack cocaine seizures were
made in 2003.
The illicit drug market in Irelandcontents
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■ With regard to market values, based on a
commonly used estimation that the amount
of drugs seized in a given year is 10% of the
total amount imported, using seizure data
provided in the Annual Report of An Garda
Síochána 2003 and price estimates supplied
by the GNDU for 2003, an approximate
estimate of the total retail market value for
the following drugs in 2003 was made:
cannabis resin €374 million; cannabis herb
€4 million; heroin €54 million; cocaine €75
million; amphetamine €10 million; ecstasy
€129 million; LSD €3,300. 
■ The largest proportions of cannabis-related
prosecutions take place in the Dublin
Metropolitan Region (DMR) and the 
Southern Region.
■ Despite the concentration of population in
the DMR, ecstasy-related prosecutions appear
to be dispersed quite widely throughout 
the State.
■ Although heroin-related prosecutions have
decreased in the DMR since 2001, they have
increased in the areas immediately
surrounding Dublin. While the trends in the
other regions are less consistent, it is clear
that, although heroin remains predominantly
a Dublin-based phenomenon, it is no longer
confined exclusively to the capital.
■ Surveys suggest that Ireland ranks quite
highly relative to other European countries in
terms of perceived drug availability. Ireland
ranks first among the 35 countries surveyed
in the most recent European School Survey
Project on Alcohol and other Drugs with
regard to perceived availability of inhalants,
crack, cocaine and ecstasy.
■ While there is not necessarily any direct
connection between source of drug
production and perceptions of availability,
these findings suggest an exaggerated
perception of drug availability among school
children in Ireland relative to those in other
European countries.
■ Localised studies and surveys which have
sought to ascertain information about local
drug markets, have found that some parts of
inner city Dublin are characterised by a high
exposure to a drug culture and that the
procurement of drugs in such areas is
relatively uncomplicated. 
■ That drug initiation usually occurs within a
familiar social context, between friends,
relatives and neighbours, rather than through
the intervention of a stranger or ‘dealer at the
school gates’, has been a consistent but
generally overlooked finding of research in
this area.
The Overview identified a number of limitations in
existing data sources and provided
recommendations for further research. The
recommendations included the following: 
■ Research is required to identify the
operational characteristics and dynamics of
different stages of the drugs market,
involving, in particular, the middle and local
market stages. Research should also
distinguish between markets in different
substances.
■ Regular surveys on the impact of local drug
markets on local communities should be
conducted. Such research would assist in
evaluating the effectiveness of intervention
strategies such as local policing initiatives.
■ Research on Irish drug markets could be
facilitated through a more systematic
collation of drug seizure, price and purity
information.
■ An analysis of seizure data might usefully
consider, separately, seizures by the various
agencies such as the Garda Síochána and
Customs and Excise. Seizures by these
different agencies would normally happen at
different stages of the market. 
■ Seizure data should also be presented in a
way whereby small and large seizures can be
defined and also whereby seizures can be
categorised by drug type. 
■ The use of price as an indicator of drug
availability requires repeated accurate and up-
to-date data. 
■ Drug purity data is not collated in a
systematic way at different market levels in
Ireland. Research should be conducted in the
Forensic Science Laboratory to ascertain
purity levels of different drugs and for
different-sized seizures, i.e. both street-level
and larger seizures.
■ Research should be conducted in order to
estimate the total value of the wholesale and
retail illicit drug markets. The compilation on
an annual basis of data on drug production
estimates, drug seizures, drug prices
(wholesale and retail), drug purity (wholesale
and retail) and drug prevalence and
estimated per capita drug consumption
would facilitate such a study. (Johnny
Connolly)
1. Connolly J (2005) The illicit drug market in
Ireland. Overview 2. Dublin: Health Research
Board. Copies of this publication can be
obtained from the National Documentation
Centre on Drug Use.
The illicit drug market in Ireland (continued)
Local drug
markets can
also instil fear
and insecurity 
in local
communities.
Consequently,
there is a need
to identify and
disrupt local
drug sources
and supply
routes.
Regular surveys
on the impact of
local drug
markets on local
communities
should be
conducted. Such
research would
assist in
evaluating the
effectiveness of
intervention
strategies such
as local policing
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Hope and colleagues1 examined the association
between injury and alcohol among persons
attending accident and emergency (A&E)
departments using the protocol developed by the
World Health Organization for its collaborative
research on alcohol and injury. The study was
conducted in six major acute hospitals across
Ireland. Between April 2003 and May 2004 and
between the hours of 10 am and 6 am, 2,500
patients aged 18 years or over who presented to
A&E within six hours of an injury were invited to
participate in the study; 2,093 (84%) agreed to
participate. The participants completed a
questionnaire covering the type and cause of
injury; alcohol consumption in the six hours prior
to injury; usual frequency and consumption of
alcohol, including the number of high-
consumption periods, in the previous 12 months;
and indicators of alcohol dependency and alcohol-
related problems. The patients who reported
drinking alcohol prior to injury were breathalysed
to estimate their blood alcohol concentration. Data
were analysed to increase understanding of risk
factors and to identify possible screening
procedures for problem alcohol use. 
Of the 2,085 patients who participated, 478 (23%)
had an alcohol-related injury and 1,607 (77%) had
a non-alcohol-related injury. Higher proportions of
participants who had an alcohol-related injury were
male or unemployed when compared to the
corresponding proportions who had a non-alcohol-
related injury (Table 1). Higher proportions of
participants who had an alcohol-related injury were
seen between Friday and Monday and between
midnight and 6 am, while the converse was
observed for those with non-alcohol-related injury.
Over half the participants with an alcohol-related
injury arrived at the A&E department within one
hour, compared to 23% of those with a non-
alcohol-related injury. Blunt force injury was more
common among participants with an alcohol-
related injury than among those with a non-
alcohol-related injury, 14% compared to 9%. Both
intentional self-inflicted injury and intentional injury
by someone else were more common among
participants with an alcohol-related injury than
among those with a non-alcohol-related injury.
Participants with alcohol-related injury were more
commonly injured in a public place (pub or street). 
Alcohol and injuries in the accident and
emergency department – a national
perspective
Table 1   Characteristics of patients who participated in the study, by type of injury
Non-alcohol-related injury Alcohol-related injury
Number of cases 1607 478
Gender Male 62.2% 73.8%
Female 37.8% 26.2%
Age group (in years) 18–29 44.5% 47.6%
30–49 29.0% 30.8%
50–64 12.6% 14.5%
65 or over 13.9% 7.1%
Employed Yes 55.6% 46.0%
No 44.1% 52.5%
Formal education (average, in years) 13.6 12.5
Monthly income (average, in Euro) 1,707 1,533
Of the 478 participants who had an alcohol-related
injury, 32% had consumed 5 to 11 drinks and
61% had consumed 12 or more drinks in the six
hours prior to the injury. Higher proportions of
participants aged 18 to 29 years or male engaged
in harmful drinking, when compared to their older
or female counterparts. Over two-thirds attributed
their injury to alcohol. Just over 70% of
participants had a blood alcohol level greater than
79 mg per 100 ml (above the legal limit for
driving) and 48% had a blood alcohol level greater
than 100 mg per 100 ml. At clinical assessment,
77% were classified as moderately or severely
intoxicated. 
The typical drinking habits among patients with
alcohol-related injuries, in comparison to those
with non-alcohol-related injuries, indicated that
higher proportions drank alcohol daily, drank at
least weekly, drank higher quantities per occasion,
and engaged in hazardous or harmful drinking at
least weekly. All of these practices were higher
among both male and female patients with
alcohol-related injuries than among those with
non-alcohol-related injuries. 
Two screening tools were used to identify problem
alcohol use and the results indicated that higher
proportions of those with an alcohol-related injury
Higher
proportions of
participants who
had an alcohol-
related injury
were seen
between Friday
and Monday and
between midnight
and 6 am, while
the converse was
observed for
those with non-
alcohol-related
injury.
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had a positive score (indicating problem alcohol
use) compared to the proportions with a non-
alcohol-related injury (Figure 1). In addition, 13%
of patients with alcohol-related injuries ‘needed to
drink more to get the same effect’ compared to
2% of those with non-alcohol-related injuries. 
A logistic regression model was constructed in
order to identify the independent influence of each
factor on whether you had an alcohol-related
injury. After controlling for the influence of other
factors, those who were most likely to attend an
accident and emergency with an alcohol-related
injury were those who:
■ presented at A&E between midnight and 6
am
■ presented at A&E at the weekend
■ presented at an inner city hospital
■ reported hazardous drinking at least monthly
■ responded positively to more than one of the
problem-alcohol indicators
■ were injured on the street or road
■ reported a lower socio-economic status.
According to the authors, the results of the
discriminate function analysis indicated that
patients who consume any alcohol and who screen
positive for two or more of the four questions
listed below should be provided with a brief
intervention to motivate them to address their
problematic alcohol use. The possible
categorisation of responses and scoring technique
for responses are not provided in the report. 
1. In the past 12 months, how often did you
drink between 5 and 11 drinks on one
occasion?
2. In the past 12 months, have you had feelings
of guilt or remorse after drinking?
3. In the past 12 months, has a family member
or friend told you about things you said or
did while you were drinking that you could
not remember?
4. In the past 12 months, how often did you
drink 12 or more drinks on one occasion? 
The authors recommend that screening for, and
brief interventions to address, problematic alcohol
use be introduced in A&E departments throughout
Ireland. (Jean Long)
1. Hope A, Gill A, Costello G, Sheehan J, Brazil E
and Reid V (2005) Alcohol and injuries in the
accident and emergency department – a national
perspective. Dublin: Department of Health and
Children.
Alcohol and injuries in the accident and emergency department
– a national perspective (continued)
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Figure 1  Indicators of problem alcohol use using the four-item Rapid Alcohol
Problems Screen, by type of injury
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On 15 December 2005 the Tánaiste and Minister for
Health and Children, Mary Harney TD, launched the
Alcohol Marketing Communications Monitoring Body. It
will oversee the implementation of and adherence to
voluntary codes of practice intended to limit the exposure
of young people (aged under 18 years) to alcoholic drink
advertising via cinema, TV, radio or outdoor/ambient
media. 
The voluntary codes were drawn up by the Drinks
Industry Group of Ireland, the Association of Advertisers
in Ireland and representatives of the media in response
to concerns raised by the Department of Health and
Children. The codes cover both the content and the
placement of alcohol advertisements. The Monitoring
Body will comprise representatives of the Health
Promotion Unit of the Department of Health and
Children, the Broadcasting Commission of Ireland, the
Drinks Industry Group of Ireland and the Advertising
Standards Authority. Peter Cassells, Chair of the National
Centre for Partnership and Performance, will be the
independent chair. 
The Tánaiste stated that she will be receiving an annual
report from the Monitoring Body, which will document
breaches of the codes. If it is apparent that the voluntary
control system is not performing credibly or effectively,
she will have ‘no hesitation’ in progressing the Alcohol
Products Bill, designed to restrict alcohol advertising and
marketing practices by law.1 
It may be anticipated that the first annual report of the
Monitoring Body will be published in early 2007. In
reading this report, interest will focus on two questions -
the effectiveness and sufficiency of the voluntary codes
and self-regulation by alcohol advertisers, as opposed to
regulation by law; and the balance between the
competing interests of government, the public and the
alcohol industry on the Monitoring Body and its impact
on policy outcomes. 
Recent Irish research and inquiries have not reached
consensus on how best to control alcohol advertising.
There have been recommendations for revisions of the
advertising codes and the establishment of effective
monitoring,2 for self-regulation by means of a steering
group including the drinks and advertising industries to
establish an independent monitoring mechanism to
ensure compliance with codes and regulations,3 for
legislative controls,4 and for an outright ban on alcohol
advertising.5
It is evident that, at EU level, there is a similar lack of
consensus on the most appropriate means of ensuring a
reduction in the exposure of young people to alcohol
advertising and of ensuring that commercial
communications do not encourage excessive or harmful
use of alcohol. In a discussion paper on a possible EU
alcohol strategy to complement national policies,6 the
European Commission has proposed a series of actions,
which indicate a continuing exploration of the options: 
■ Analyse the experiences of regulatory and self-
regulatory mechanisms in the member states.
■ Examine how the application of Article 15 of the
Television without Frontiers Directive could be more
effective, for example in relation to volume, timing,
context and placement of advertisements and how
to increase the awareness of benefits to consumers. 
■ Participate in a process of co-regulation, whereby
self-regulatory approaches adopted by the beverage
alcohol industry are monitored by an independent
body.
■ Use research findings as the basis of measures to
reduce commercial communication to young people. 
In a further twist in the debate, the authors of a recent
survey of alcohol-related research and public policy7 found
that not only has sophisticated alcohol marketing
facilitated the recruitment of new cohorts of young people
to the ranks of heavier drinkers but it has also worked
against health promotion messages. Pending a resolution
of the debate on how effectively to reduce the impact of
alcohol advertising on young people, the authors suggest
that policy makers should seek to ensure ‘a more level
playing-field for the reception of health promotion
messages by the young’. (Brigid Pike)
1. For further information on the Alcohol Marketing
Communications Monitoring Body and the voluntary
codes, visit the website of the Department of Health
and Children at www.dohc.ie 
2. Dring C and Hope A (2001) The impact of alcohol
advertising on teenagers in Ireland. Dublin: Department
of Health and Children.
3. Strategic Task Force on Alcohol (2002) Interim report.
Dublin: Department of Health and Children.
4. Strategic Task Force on Alcohol (2004) Second report.
Dublin: Department of Health and Children. See S
Power (2005, 6 October) Parliamentary Debates Dáil
Éireann Official Report: Unrevised. Vol. 607, col.
122–123 for a justification of the government’s
decision to ignore the Task Force’s recommendation to
legislate: ‘The Department is satisfied that the code [as
opposed to legislative controls] will result in a
significant reduction in the exposure of young people
to alcohol advertisements, which is the aim of the
recommendation of the task force.’
5. Joint Committee on Health and Children (2004)
Report on alcohol misuse by young people. Dublin:
Houses of the Oireachtas.
6. See ‘Discussion paper on the EU strategy on alcohol’,
prepared by officials in the Health & Consumer
Protection Directorate-General of the European
Commission, for a meeting of the Working Group on
Alcohol and Health on 7–8 March 2005 in
Luxembourg. 
7. Babor T, Caetano R, Casswell S et al. (2003) Alcohol:
No ordinary commodity – research and public policy.
Oxford: Oxford University Press. 
Self-regulation of alcohol advertising is on
probation
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New information on cocaine use in Ireland
On 12 January 2006, the National Advisory
Committee on Drugs (NACD) in Ireland and the
Drugs and Alcohol Information and Research Unit
(DAIRU) within the Department of Health, Social
Services and Public Safety in Northern Ireland
published jointly the fourth bulletin of results from
the 2002/2003 all-Ireland general population drug
prevalence survey.1 This latest bulletin focuses on
cocaine use in the adult population (15–64 years)
and patterns of cocaine use. Minister of State with
responsibility for drugs strategy, Mr Noel Ahern
TD, launched the findings for Ireland. This article
highlights some of those findings and, in addition,
presents unpublished data from the National Drug
Treatment Reporting System (NDTRS).
Of the 4,918 survey respondents, 3% reported that
they had used some form of cocaine at least once in
their lives (ever use). Just over 1% had used cocaine
in the last year (recent use). Only 0.3% had used it
in the last month (current use). Of those who had
used cocaine, the vast majority reported that they
used cocaine powder; crack cocaine use was rarely
reported. A higher proportion of younger (15–34
years) respondents had ever used cocaine (4.7%)
compared to the proportion of older (35–64 years)
respondents (1.4%). More male respondents (4.3%)
had ever used cocaine than female respondents
(1.6%). Half of all cocaine powder users
commenced cocaine use before they were 20 years
old, while half of all crack users commenced before
they were 22 years old. There were 27 self-defined
regular users of cocaine powder. 
Of the 17 current cocaine powder users, just over
83% used cocaine less than once per week, while
just under17% used it at least once per week. Just
over 83% of current cocaine powder users snorted
the drug, while no respondent injected it. 
Of the 51 recent cocaine powder users, just over
28% obtained their cocaine from a person who
was not known to them, indicating that cocaine
use introduces people to cohorts of other users;
this may have negative public health implications.
Cocaine powder was most commonly obtained at
the home of a friend (52%) or at a disco, bar or
club (38%). Just under 68% of recent cocaine
powder users said that cocaine powder was easy to
obtain within a 24-hour period. 
Of the 27 self-defined regular cocaine powder
users, almost 62% had successfully stopped taking
cocaine. The most common reasons for
discontinuing it were: could no longer afford it
(42%), did not want to continue using it (35%),
were concerned about its health effects (32%) and
were influenced by family and friends (32%). 
The findings of this study should be interpreted
with care, in view of the small number of responses
on which the patterns of cocaine use are based. It
should also be noted that there are special
methods, such as nomination or snowballing
techniques, to locate and interview drug users so as
to investigate patterns and practices of cocaine or
opiate use. In addition, a considerable proportion
of the socially excluded population are unlikely to
be represented in a general population survey. This
is because they are unlikely to be included in a
population-based list, as they do not reside at a
fixed address or, if listed, are difficult to locate for
interview. Studies have shown higher rates of
problematic drug use among those living in areas
classified as high deprivation, and among the
homeless and the prison population.2-4
Analysis from the NDTRS indicates a sustained
increase between 1998 and 2003 in the number of
treated cases reporting cocaine as a problem drug,
particularly as an additional problem drug among
opiate users. The number of treated cases reporting
cocaine as a main problem drug increased by
262%, from 86 in 1998 to 311 in 2003 (Table 1).
Of the 311 who reported cocaine as their main
problem drug in 2003, 92% used one or more
additional drugs. The number of cases reporting
cocaine as an additional problem drug increased by
almost 400%, from 454 in 1998 to 2,244 in 2003
(Table 2). When cocaine was reported as the main
problem drug, cannabis, alcohol and ecstasy were
the most common additional problem drugs,
whereas when cocaine was reported as an
additional problem drug the most common main
problem drugs associated with its use were opiates,
cannabis and ecstasy (Table 3).
Of those who had
used cocaine, the
vast majority
reported that
they used cocaine
powder; crack
cocaine use was
rarely reported.
The findings of
this study should
be interpreted
with care, in view
of the small
number of
responses on
which the
patterns of
cocaine use are
based.
Table 1   All cases treated for cocaine as a main problem drug in Ireland and reported to
the NDTRS, 1998 to 2003
1998 1999 2000 2001 2002 2003
Number (%)
All cases reported 6035 6206 6933 7900 8596 9084
Cocaine as main problem drug 86 (1.4) 57 (0.9) 78 (1.1) 95 (1.2) 155 (1.8) 311 (3.4)
Of whom:
New cases 32 27 33 46 65 157
Previously treated cases 50 29 42 41 76 145
Treatment status not known 4 1 3 8 14 9
Source: Unpublished data from the NDTRS
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In 2003, of the 311 treated cases who reported
cocaine as their main problem drug, 68% snorted it,
16% injected it, and 12% smoked it. Cocaine use by
the same 311 cases in the month prior to treatment
was reported as follows: 23% used it daily, 37% used
it 2 to 6 days per week, 10% used it once per week
or less and 24% had not used it. Of note, no
respondent participating in the NACD/DAIRU
population-based survey reported injecting cocaine,
compared to approximately one in seven of the
treated cases. As expected, the frequency of cocaine
use among treated cases was considerably higher
than that among the general survey population. 
In 2003, half of the treated cases for whom
cocaine was the main problem drug had
commenced its use before they were 20 years old
and 80% were men. In 2003, there were 2,555
treated cases who reported cocaine as one of their
problem drugs, 1,929 lived in the eastern region
(Dublin, Kildare or Wicklow) while 613 lived
elsewhere in Ireland. The demographic
characteristics for the treated cases are similar to
those of the survey respondents. (Jean Long)
1. National Advisory Committee on Drugs and
Drug and Alcohol Information and Research Unit
(2006) Drug use in Ireland and Northern Ireland.
2002/2003 drug prevalence survey: cocaine
results. Bulletin 4. Dublin: NACD.
2. Barry J, Sinclair H, Kelly A, O'Loughlin R, Handy
D, O'Dowd T (2001) Inequalities in health in
Ireland: hard facts. Dublin: Trinity College.
3. Lawless M, Corr C (2005) Drug use among the
homeless population in Ireland: a report for the
National Advisory Committee on Drugs. Dublin:
Stationery Office.
4. Allwright S, Barry J, Bradley F, Long J, Thornton L
(1999) Hepatitis B, hepatitis C and HIV in Irish
prisoners: prevalence and risk. Dublin: Stationery
Office.
New information on cocaine use in Ireland (continued)
Table 2   All cases treated for cocaine as an additional problem drug in Ireland and
reported to the NDTRS, 1998 to 2003
1998 1999 2000 2001 2002 2003
Number (%)
All cases reporting an 
additional problem drug 4261 4317 4895 5378 6518 6891
Cocaine as a second, third
or fourth problem drug 454 (10.7) 786 (18.2) 916 (18.7) 1220 (22.7) 1716 (26.3) 2244 (32.6)
Of whom:
New cases 92 180 189 226 309 443
Previously treated cases 355 598 711 968 1367 1772
Treatment status not known 7 8 16 26 40 29
Source: Unpublished data from the NDTRS
Table 3   Main problem drug and associated additional drugs used by new cases treated
in Ireland and reported to the NDTRS, 1998 to 2003
Main problem drug used by new cases 
reporting more than one problem drug
Opiates Ecstasy Cocaine Amphet- Benzo- Volatile Cannabis
amines diazepines inhalants
Additional problem 
drug used*
Other opiates 870 24 52 4 19 2 124
Ecstasy 590 155 71 17 15 1968
Other cocaine 772 164 2 22 11 2 469
Amphetamines 124 299 62 4 4 692
Other benzodiazepines 1178 24 10 3 14 2 92
Other volatile inhalants 23 21 1 9 106
Other cannabis 2015 690 220 79 30 47 6
Alcohol 254 377 118 29 63 44 1743
*by those who used between one and three additional drugs
Source: Unpublished data from the NDTRS
In 2003, there
were 2,555
treated cases
who reported
cocaine as one of
their problem
drugs
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Government bans sale of ‘magic’ mushrooms
An order under the Misuse of Drugs Act 1977
provides that, from 31 January 2006, ‘any
substance, product or preparation (whether natural
or not), including a fungus of any kind or
description, which contains psilocin or an ester of
psilocin is a controlled drug for the purposes of the
Act’.1 The effect of this order is to render the
possession or sale of so-called ‘magic’ mushrooms
criminal offences under the Act. Heretofore, it was
illegal to possess or supply magic mushrooms in a
dried or prepared state but lawful to possess and
sell them in their natural state.
In 2005 the National Advisory Committee on
Drugs (NACD) and the Drugs and Alcohol
Information and Research Unit (DAIRU) of the
Department of Health, Social Services and Public
Safety in Northern Ireland published jointly the
first results from an all-Ireland general population
drug prevalence survey.2 Some of the findings
relating to Ireland from this survey are presented
in Table 1.
It can be seen from Table 1 that, when we
compare lifetime prevalence with last-year
prevalence of magic mushroom use among young
adults, the rate drops significantly, from 5.9% to
0.7%. This suggests that magic mushrooms are
used by young adults largely as an experimental
drug. The same can be said of LSD.
A survey of 1,838 school-going teenagers (aged
13–18) in Kildare and west Wicklow found that the
lifetime prevalence of magic mushroom use was
5% (number 94); 37% of those reported current
use.3 The mean age of first use was 13.6 years,
with more males (45%) than females (20%)
reporting persistent use. A survey of drug
availability in Kilkenny found that magic
mushrooms were ‘extremely popular, when in
season’.4 In the past two years, magic mushrooms
have been available for sale in over 300 locations
in the UK and in a number of locations in Dublin
and elsewhere in Ireland.
The risks associated with magic mushrooms can vary
depending on the mood, situation and expectation
of the user.5 Among the reported effects are feelings
of confidence, visual and sound distortions, paranoia
and vomiting. A recent risk assessment conducted
by the Netherlands-based Coordination Centre for
the Assessment and Monitoring of new drugs (CAM)
concluded: ‘This drug is not associated with physical
or psychological dependency, acute toxicity is largely
limited to possible panic and anxiety attacks and, in
terms of chronic toxicity, the worst that can happen
are flashbacks. Consequently, the use
of…hallucinogenic mushrooms does not, on
balance, present any risk to the health of the
individual’.6 As magic mushrooms can be sold in
outlets in the Netherlands, the report recommended
that quality requirements (standardisation, purity
testing and labelling) be imposed on such outlets.
There is a lack of scientific evidence on the overall
effects of magic mushroom consumption. There is
no reported evidence of serious health damage
from long-term use of magic mushrooms. The
average dosage is 20–30 mushrooms; however,
tolerance can develop quickly and dosages
increase as a result. A risk associated with magic
mushrooms is poisoning through picking and
consuming the wrong type of mushroom. 
Following the change in the law in January, it is
reported that a number of outlets which were
selling magic mushrooms have removed them
from their stores and shelves. (Johnny Connolly)
1. Misuse of Drugs Act 1977 (Controlled Drugs)
(Declaration) Order 2006.
2. National Advisory Committee on Drugs and
Drug and Alcohol Information and Research Unit
(2005) Drug use in Ireland and Northern Ireland:
first results (revised) from the 2002/2003 drug
prevalence study. Bulletin 1. Dublin: NACD
3. Cahill R, O’Neill I, Barnett T, Fogarty C,
McDermott R and Keenan E (1999) Substance
use in school going teenagers in Co. Kildare and
west Wicklow. Dublin: Eastern Health Board.
4. Finane R (2000) Kilkenny drugs initiative:
substance misuse research findings and action
plan. Kilkenny: Kilkenny Drugs Initiative. p. 8.
5. For a review of the effects of magic mushrooms,
see: www.drugscope.org.uk 
6. Coordination Centre for the Assessment and
Monitoring of new drugs (CAM) (2000) Risk
assessment report relating to psilocin and
psilocybin. The Hague: CAM. p. 5.
Table 1  Lifetime and last-year prevalence of cannabis, ecstasy, LSD and magic 
mushroom use by young adults (aged 15–34) in Ireland
Drug Lifetime prevalence Last-year prevalence
(ever used) (used in the last year)
% %
Cannabis 24.0 8.6
Ecstasy 7.1 2.3
Magic mushrooms 5.9 0.7
LSD 4.6 0.2
Source: NACD and DAIRU (2005)
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The seventh annual Service of Commemoration
and Hope, organised by the Family Support
Network, was held in Our Lady of Lourdes Church
on Sean McDermott Street on 1 February. This
year’s service focused on the effects of drug use in
the home and the importance of involving young
siblings in the support process for the family
member affected by drugs. 
Sadie Grace of the Family Support Network
highlighted the effect of drug use on the user’s
family. The Network is currently working to identify
a strategy that will include schools and other
agencies in supporting these young children both
within and outside of the school system. Ms Grace
said that the acknowledgement of the role of
families in the mid-term review of the National
Drugs Strategy was welcome. The mid-term review
states that the National Drugs Strategy Team
(NDST) should actively encourage local and
regional drugs task forces to prioritise the provision
of family support services in their areas and action
plans. However, the task forces need to be more
proactive and the NDST should insist that they
include family support as part of their action plans. 
The launch of the National Drug-Related Deaths
Index (NDRDI) in 2005 was a very positive
development. The NDRDI will provide a more
complete and accurate reporting of drug-related
deaths and deaths among drug users, which will
inform policy and practice in the harm reduction
and prevention areas. This information will enable
the Family Support Network to lobby for services
that bereaved families need.
Mr Noel Ahern TD, Minister of State with
responsibility for drugs strategy, and Bishop
Eamonn Walshe also addressed the gathering. A
drama piece, Paulie and Johnny, based on a true
story of two brothers, one of whom dies as a result
of drug use, was part of the event, as well as a
circle of remembrance formed by representatives
of support groups from Ireland, Northern Ireland
and Scotland, and a performance by singer Christy
Moore. Young people from various local youth
groups displayed art work on the theme ‘Drugs
past and future’. (Ena Lynn)
The Family Support Network was established by
the CityWide Drugs Crisis Campaign
(www.citywide.ie).
Seventh annual Service of
Commemoration and Hope 
NACD research seminars
Word on the Street youth group from Blakestown
created this sculpture with the help of artist Grace
Boon.  The project was supported by Fingal
County Council Arts Office and City of Dublin VEC.
The sculpture uses modelled syringes combined
with faces, hands and a small figure to
commemorate the loved ones lost to drugs. The
light placed at the centre of the sculpture
represents a symbol of hope for the future and the
determination of our young people to embrace
their lives with love and joy. (Photo: Jim Berkeley)
In December 2005 the National Advisory
Committee on Drugs (NACD) hosted the first of a
series of seminars entitled ‘Commissioning and
managing research’ in Dublin. The seminars were
designed to increase awareness of this subject
among local and regional drugs task forces. The first
seminar covered each stage of the research process
from the development of research ideas and
refinement of objectives to commissioning research,
monitoring progress and preparing the final draft
for publication. Ms Mairéad Lyons and Dr Aileen
O’Gorman of the NACD, a body with several years’
experience in these areas, presented an outline of
the research process and explained practical issues
such as procurement and contracts. Dr Jean Long
and Brian Galvin of the Drug Misuse Research
Division (DMRD) described the division’s research
and information-gathering role, emphasising the
importance of surveillance systems, and the work of
the DMRD in disseminating research findings.
Professor Des Corrigan, NACD chair, also addressed
the seminar. Ms Patricia O’Connor of the National
Drugs Strategy Team explained how the Emerging
Needs Fund will operate. 
The response to the seminar was very positive and
participants felt that they had been given a good
general grasp of the issues involved in carrying out
or commissioning research. It was generally agreed
that ethical issues and the use of qualitative
research in the drugs area could usefully be
discussed in more detail. Further seminars were
held in Dublin in February and in Portlaoise and
Carrick-on-Shannon in March. (Brian Galvin)
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The Irish Prison Service (IPS) annual report for
20041 was released in December 2005. The mission
of the IPS is to provide safe, secure and humane
custody for people who are sent to prison. The IPS
aims to provide a range of care and rehabilitation
services for prisoners. These services are important
in sustaining prisoners’ physical and mental health
and ensuring equivalence of care with the health
services available in the community. The services
included are medical, dental, psychiatric,
psychological and counselling. 
The provision of drug treatment services, in
particular methadone services, continues to use a
significant proportion of health care resources. A
number of prisons provide methadone treatment
and, in 2004, 1,309 prisoners were treated with
methadone. Of these, 96 commenced methadone
treatment for the first time, indicating the
important role of prison services in introducing
prisoners to drug treatment (Table 1). 
The IPS recognises that people who take drugs
require assistance in order to tackle their addiction
successfully. Meeting the needs of drug users
requires a variety of interventions tailored to each
individual. According to the authors, the dramatic
increase in methadone treatment over the past five
years and the consequent demand for a range of
drug treatment services in prisons highlight the
need for a review of the structures and staff
required to deliver these services. The authors state
that there are some pilot initiatives in place that
could be useful if provided throughout the prison
service. For example, two nurses have been
allocated to the delivery of drug treatment services
in Wheatfield Prison, which has considerably
improved the continuity of care for drug users
within the prison and, more importantly, between
the prison and the community.
Developments in health care in Irish
prisons in 2004
The first
recommendation
in the report of
the review group
is that the same
care and
treatment should
be available in
both the prison
and community
health services. 
From 2004
onwards, prison
entrants are
provided with an
outline of the
level of services
they may expect
to receive.
Table 1   Number of cases receiving methadone treatment in Irish prisons in 2004
Number registered with the Central Treatment List in 2004 
Prisons All cases New cases
Cloverhill Prison 528 71
Dochas Centre 211 12
Limerick Prison 3 0
Mountjoy Main Prison (including Medical Unit) 394 6
Midland Prison 6 0
Portlaoise Prison 6 0
St Patrick’s Institution 3 0
Wheatfield Prison 158 7
Total number 1309 96
The Prison Health Working Group (PHWG) is
responsible for implementing the
recommendations of a review group on the
structure and organisation of prison services
published in 2001.2 The re-organisation of the
health service management structures resulted in
delayed implementation of some of these
recommendations. However, the PHWG has
completed a large body of work which has been
submitted for consideration and includes:
■ a health-needs assessment of the Irish prison
population
■ a report on meeting the mental health needs
of prisoners
■ a protocol in relation to the management of
prisoners attending acute hospitals.
The first recommendation in the report of the
review group is that the same care and treatment
should be available in both the prison and
community health services. In order to implement
this recommendation, considerable groundwork
was undertaken during 2004 to develop formal
service agreements in a number of areas. For
example, formal agreements will be developed
between Cloverhill and Wheatfield prison services
and the health sector in order to provide
consultant-led infectious disease and drug
treatment services at these prisons from 2005
onwards. Of course, the effective development of
these services within the prisons will require
adequate and appropriate internal administrative
and clinical support. The experience gained from
the introduction of these services in Cloverhill and
Wheatfield prisons will facilitate similar
developments across the prison estate.
The Irish Prison Service Health Care Standards
manual was published in June 2004. This provides
governors and other managers with clear guidance
regarding the health services to be provided and
the facilities required to provide these services.
From 2004 onwards, prison entrants are provided
with an outline of the level of services they may
expect to receive.
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The feasibility of formally incorporating the prison
population within General Medical Service (GMS)
structures so as to facilitate treatment structures in
custody, and in the period immediately following
release, is under consideration. Progress in this
matter will require a formal acceptance that
prisoners should be covered within the same
administrative structures as other citizens.
The resolution of the prison doctors’ strike resulted
in a new contract which benefits both the doctors
and the prison services. As part of the contract,
doctors are required to implement a range of
clinical and administrative tasks. These tasks are in
line with the specifications in the IPS health care
standards and are necessary for the effective and
co-ordinated provision of health care within a
custodial environment and between the prisons
and the community.
A nursing service was introduced in Irish prisons in
1999. There are 79.5 whole-time-equivalent
nursing officers providing health care in 11 of the
16 prisons. (Siobhan Reynolds)
1. Irish Prison Service (2005) Annual Report 2004.
Dublin: Irish Prison Service.
2. Report of the group to review the structure and
organisation of prison health care services (2001)
Dublin: Stationery Office.
Developments in health care in Irish prisons in 2004 (continued)
Trends in alcohol and drug disorders in
psychiatric hospitals
The latest annual report on activities in psychiatric
inpatient units and hospitals in 2004 shows that
the total number of admissions to inpatient care
continues to fall.1 There is an increase in
admissions to general hospital psychiatric units and
a decline in use of psychiatric hospitals. The report,
Activities of Irish Psychiatric Services 2004, was
published in December 2005 by the Health
Research Board (HRB) and is the latest in a series
that began forty years ago.
Figure 1 presents the rate of first admissions to
inpatient psychiatric services with a diagnosis of
alcohol disorder, per 100,000 of the population in
Ireland between 1990 and 2004.1,2,3 It is notable
that the rate of alcohol-related admissions
decreased steadily between 1991 and 2004 and
more than halved during the reporting period. This
reflects changes in alcohol treatment policy and
practices during the period and the resultant
increase in community-based and special
residential alcohol treatment services. 
Figure 2 presents the rate of first admissions to
inpatient psychiatric services with a diagnosis of
drug disorder, per 100,000 of the population in
Ireland between 1990 and 2004.1,2,3 It is notable
that the rate increased steadily between 1990 and
1995, with a dip in 1996, and further annual
increases between 1997 and 2001. The rate of
drug-related admissions was almost three times
higher in 2001 than it was in 1990.  The dips in
1996 and 2002 can be partly explained by the fact
that the rates are calculated from new larger
census numerators in 1996 and 2002 compared to
the year preceding each of these years and the
It is notable that
the rate of
alcohol-related
admissions
decreased
steadily between
1991 and 2004
and more than
halved during the
reporting period. 
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Figure 1  Rate of psychiatric first admissions with a diagnosis of alcohol disorder
(using the ICD-10 three character categories) per 100,000 of the population
in Ireland and reported to the NPIRS, 1990 to 2004
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Trends in alcohol and drug disorders in psychiatric hospitals
(continued)
small number of drug dependence cases each year
would be sensitive to this change in numerator.
The increasing rate of new cases of drug-related
admissions between 1990 and 2001 reflects the
increase in problem drug use in Ireland and its
burden on the psychiatric services.  There was a
notable decrease in 2002, which was sustained in
2003.  This overall decrease since 2001 possibly
reflects an increase in community-based specialised
addiction services during this period. (Jean Long)
1. Daly A, Walsh D, Moran R and Kartalova-
O'Doherty Y (2004) Activities of Irish Psychiatric
Services 2003. Dublin: Health Research Board.
2. Daly A, Walsh D, Comish J, Kartalova-O’Doherty
Y, Moran R and O’Reilly A (2005) Activities of
Irish psychiatric units and hospitals 2004. Dublin:
Health Research Board.
3. Walsh D and Daly A (2004) Mental illness in
Ireland 1750-2002: reflections on the rise and fall of
institutional care. Dublin: Health Research Board.
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In November 2005 €34.027 million was voted for
the Drugs Initiative, which funds the local and
regional drugs task forces, and the Young People’s
Facilities and Services Fund (YPFSF), in 2006 – an 8
per cent increase on the allocation for 2005 and
‘well in excess of inflation’ according to the
government.1 The community sector strongly
criticised this estimate, calling for an additional €8
million to €15 million, to fund the projects
identified following the creation of the Emerging
Needs Fund in January 2005.2 In January 2006,
the government revised its drugs estimate upwards
by a further €8.979 million.3
As well as criticising the 2006 drugs estimate, the
community sector raised a series of concerns with
regard to governance – the rules, processes and
behaviour that affect the way in which powers are
exercised4 – or, in short, decision-making with
regard to drugs policy in Ireland.
Lack of political interest in the drugs issue is one
concern. As long ago as June 2002 the CityWide
Drugs Crisis Campaign was calling for drugs to be
‘put back on the political agenda’, and it has
mounted a similar campaign again this year.5 It is
argued that making the Minister of State with
responsibility for drugs also responsible for housing
and urban renewal has weakened his commitment
to and energy for addressing the drugs issue. At the
time of his appointment, Minister of State Noel
Ahern TD argued that assigning him responsibility
for both housing and urban renewal and drugs
‘made sense’ because ‘there is an overlapping or at
least shared responsibility between estate
management, which local authorities do, and some
of the other good work that drug task forces and
the youth facilities and services programme do, and
it is an attempt to pull these strands together.’6
Regarding political interest in general in the drugs
issue, Action 77 of the National Drugs Strategy7
2006 drugs estimate refuels debate on
governance issues
The rate of 
drug-related
admissions was
almost three
times higher in
2001 than it was
in 1990.
Figure 2  Rate of psychiatric first admissions with a diagnosis of drug disorder (using
the ICD-10 three character categories) per 100,000 of the population in
Ireland and reported to the NPIRS, 1990 to 2004
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called for the establishment of a sub-committee of
the existing Oireachtas Committee on Arts, Sport,
Tourism, Community, Rural and Gaeltacht Affairs
specifically to consider drugs. This innovation
would have drawn public representatives from
across the political spectrum more directly into
debate on the drugs issue. The Steering Group for
the Mid-Term Review of the National Drugs
Strategy8 concluded, however, that this proposal
was unworkable ‘partly due to the wide range of
responsibilities of that Committee’, and proposed
instead that the Minister of State with responsibility
for drugs should appear before the full Oireachtas
Committee twice a year (Section 7.23).
In its protest against the 2006 drugs estimate, the
community sector also called for the reinstatement
of the agreed government process to support the
work of the LDTFs, the evaluation and
mainstreaming of successful LDTF initiatives and
projects, and a mandate for the LDTFs to
undertake three-year strategic planning that will
support an efficient, integrated and co-ordinated
approach.2 In short, the community sector is
dissatisfied with the way the partnership between
government and the community and voluntary
sectors in tackling the drugs issue is operating. 
During the past year, Pat Rabbitte TD, chair of the
1996/97 Ministerial Task Force on Measures to
Reduce the Demand for Drugs, has claimed that
implementing the National Drugs Strategy has
become a bureaucratic process and that the
community sector is being sidelined.9 The Steering
Group for the Mid-Term Review8 similarly reported
a ‘sense of frustration’ (Section 2.28) in the
community sector with regard to resourcing for
both the LDTFs and the RDTFs, and the sector’s
view that ‘funding should be allocated on a multi-
annual basis’ (Section 2.25). While not making any
formal recommendations, the Steering Group
advised that the appointment of RDTF co-
ordinators and other staffing issues should be
addressed ‘at an early date’ (Section 7.7). It also
endorsed the mainstreaming of evaluated LDTF
projects, while noting that the obstacles, principally
the financial and audit requirements of the State
agencies through which funding for the projects is
channelled, needed to be resolved (Section 7.4). 
The Steering Group for the Mid-Term Review also
teased out weaknesses in the ways different partners
are performing within the partnership process and
interacting with other partners. On the one hand, it
noted that ‘the level of commitment of members of
LDTFs, participation of members and their
understanding of their roles, as well as discontinuity
caused by membership turnover, can impact on the
effective operation of Task Forces. The Group believes
that all partners should renew their commitment to
the LDTFs, and provide enhanced training and
support for their staff to engage fully in LDTF
activities. In line with Action 89, the NDST should
continue to focus on strengthening and supporting
community representation and participation on the
Task Forces.’ (Section 7.4) On the other hand, the
Steering Group noted that, ‘representatives of the
statutory bodies who are members of LDTFs and
RDTFs need to be mindful of their role. In particular,
they should consult with – and bring relevant
information to – their Task Forces regarding
developments at both local and national levels within
their organisations that impact on progressing actions
in the NDS. They also need to ensure that their
parent organisations are aware of developments
within the Task Forces and how those developments
impact on their agencies.’ (Section 7.8)
The Steering Group included formal
recommendations to strengthen representation of
the community and voluntary sectors at national
level, on both the Interdepartmental Group on
Drugs and on the National Drugs Strategy Team,
and to ensure adequate resourcing for the National
Drugs Strategy Team. However, it did not make any
formal recommendations to address the weaknesses
it had perceived in the processes and interactions
underpinning the partnership approach. (Brigid Pike) 
1. Department of Finance (2005, 17 November)
2006 Estimates for public services (abridged
version): Summary public capital programme.
Dublin: Stationery Office.
2. For full details of the community sector’s
demands, see www.citywide.ie/campaigns/
drugsstrategyinfo.html. Viewed on 1 February
2006. 
3. Department of Finance (2006, 23 January) 2006
Revised Estimates for Public Services. Dublin:
Stationery Office.
4. See Commission of the European Communities
(2001, 25 July) European Governance: A white
paper. COM (2001) 428 final.
5. See ‘Community sector calls for action on drugs’
in Drugnet Ireland, July 2002 (5), pp. 2–3, and
for details of current campaign, see
www.citywide.ie/campaigns/
drugsstrategyinfo.html .  
6. See ‘New minister of state with responsibility for
drug strategy’ in Drugnet Ireland, July 2002 (5),
p. 1.
7. Department of Arts, Sport and Tourism (2001)
Building on experience: National drugs strategy
2001–2008. Dublin: Stationery Office.
8. Steering Group (2005) Mid-term review of the
national drugs strategy 2001–2008. Dublin:
Department of Community, Rural and Gaeltacht
Affairs.
9. See P Rabbitte (2005, 26 May) ‘Drugs problem
has gone national in last ten years’. Address at
event marking 10th anniversary of CityWide
Drugs Crisis Campaign. Available at
www.labour.ie. Viewed on 2 June 2005. See also
P Rabbitte  (2005, 15 December) Parliamentary
Debates Dáil Éireann Official Report: Unrevised.
Vol. 612, col. 1220, PDF version. Available at
www.gov.ie/oireachtas/frame.htm
2006 drugs estimate (continued)
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Drug helplines across Europe help to identify
emerging drug trends
In November 2005 the European Foundation of Drug
Helplines (FESAT) published the results from its ninth
monitoring project.1 Since the beginning of 2001 FESAT
has been collecting information every six months on the
types of person contacting FESAT helplines, the content of
these calls and how this has changed compared to the
previous six months. The main objective of this
monitoring is to identify the emergence of new drugs and
new drug trends as early as possible. A total of 28 FESAT
helplines in 16 European countries, including Ireland,
participated in the ninth monitoring project. This article
will describe some of the main changes that were
reported by the helplines during the second half of 2004. 
While the majority of helplines reported no change in the
number and content of calls during the second half of
2004 compared to the situation during the first six
months of 2004, a number of helplines did report an
increased number of calls about cocaine (9 helplines) and
alcohol (7 helplines). There were also reports of a decrease
in the number of calls about injecting heroin (8 helplines)
and about ecstasy (8 helplines). These trends were also
noted in the eighth monitoring project, which compared
the first six months of 2004 with the last six months of
2003.2 The emergence of cocaine as a growing European
problem was recently highlighted by the European
Monitoring Centre for Drugs and Drug Addition
(EMCDDA).3
Four helplines reported calls about new drugs (i.e. drugs
not previously reported by the helpline). Calls about a
mixture of ‘cocaine and absint’ were reported by two
Belgian helplines. Calls were received about a stimulant
called ‘speed 8’ in the Czech Republic. Speed 8 contains a
GHB derivative and is sold legally in the country. A Russian
helpline received reports about the consumption of a new
substance called ‘Spidi’. The FESAT report does note,
however, that an increased number of calls about a
specific drug, that is not a part of a more general trend,
cannot automatically be seen as an indicator of increased
consumption. It might also indicate an increased curiosity
or an increased concern among professionals, parents or
partners. The report also acknowledges that it is not
possible to get a clear picture about changes in the use of
different drugs via data from drug helplines only. Hence, it
is important to see drug helpline monitoring as a
complement to other kinds of data collected nationally or
internationally.
Information for the ninth monitoring project was collected
from FESAT helplines using a standard questionnaire
distributed in February 2005. Out of a total of 41 relevant
helplines, 28 (63% response rate) returned completed
questionnaires. These helplines were based in the
following 16 countries: Austria (3 helplines), Belgium (2),
Cyprus (1), Czech Republic (1), Finland (4), Germany (2),
Greece (3), Ireland (1), Italy (2), Latvia (1), Luxembourg
(1), Malta (1), the Netherlands (2), Portugal (1), Russia (1)
and Spain (2). The participating Irish helpline was the
Drugs/HIV Helpline, based in Dublin, which handled an
average of 35 calls per day in the second half of 2004, up
from 16 per day in the first half of 2004. (Hamish Sinclair)
1. Hibell B (2005) FESAT Monitoring Project -– Changes
during the second half of 2004. FESAT (The European
Foundation of Drug Helplines). www.fesat.org
2. Hibell B (2005) FESAT Monitoring Project -– Changes
during the first half of 2004. FESAT (The European
Foundation of Drug Helplines). www.fesat.org
3. European Monitoring Centre for Drugs and Drug
Addition (2005). The state of the drugs problem in
Europe: annual report 2005. Luxembourg: Office for
Official Publications of the European Communities.
More information about FESAT can be found on the
website of the European Foundation of Drug Helplines
(www.fesat.org). The freephone number for the Irish
Drugs/HIV Helpline is 1800 459 459.
According to the Health Protection Surveillance Centre’s
annual report for 2004,1 infectious disease notifications
increased by 62% in 2004 when compared to 2003.
Hepatitis C accounted for a considerable portion of this
increase. The increase in notifications came about as a
result of an amendment to the Infectious Diseases
Regulations, which came into effect on 1 January 2004,
whereby clinicians and diagnostic laboratories are now
legally obliged to report hepatitis C as well as other
notifiable diseases. 
There were 1,154 cases of hepatitis C reported in 2004,
compared to 85 cases of hepatitis type unspecified2 in
2003. Of the cases reported in 2004, 954 were notified by
the HSE Eastern Region and 200 by HSE areas outside the
Eastern Region. Each of the seven HSE areas outside the
HSE Eastern Region reported cases of hepatitis C, ranging
from five in the North Western Area to 45 in the Southern
Area, with the average number being 29 cases. Three out
of every five hepatitis C cases reported were male. Of the
1,132 cases for whom age and gender were known, 83%
were aged between 20 and 44 years. It is estimated that
90% of people with chronic hepatitis C in developed
countries are current or former injecting drug users or
have received unscreened blood or blood products. 
There is no enhanced surveillance system for hepatitis C in
Ireland. Enhanced surveillance is essential to identify risk
factors and for planning prevention and treatment
strategies. Risk-factor identification is required to fulfil the
basic requirements of the European Monitoring Centre for
Drugs and Drug Addiction’s key indicator on drug-related
infectious diseases. (Jean Long)
1. Health Protection Surveillance Centre (2005) Annual
Report 2004. Dublin: Health Protection Surveillance
Centre.
2. Disease category under which hepatitis C cases were
notified up to the end of 2003.
Hepatitis C surveillance in 2004
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On 12 December 2005 the Misuse of Drugs
Sectoral Group of the British–Irish Council held its
fourth ministerial meeting, chaired by Minister
Noel Ahern TD, Minister of State for drugs, in
Dublin. Ministers from the different jurisdictions
represented on the British–Irish Council agreed
that members would take forward the following
issues during 2006:
■ Wales will lead on commissioning of drug
treatment services.
■ Guernsey will lead on the confiscation of
criminal assets.
■ Ireland will host a meeting on rehabilitation
for drug misusers.
■ Jersey will explore the use of Subutex as
substitution treatment for opiate misusers.
■ Northern Ireland will host a meeting on the
challenges presented by cocaine misuse –
recreational and problematic.
Meetings will be organised on each topic, at which
officials and experts will have the opportunity to
discuss ideas, explore different approaches to the
subject under discussion, exchange views,
experiences and best practice, and develop
valuable networks of contacts. Ministers agreed
that these meetings are a very useful forum for
sharing, in a focused and practical manner, the
detailed expertise and knowledge which is held
across the British–Irish Council region. They also
noted that, in addition to exploring specific
themes in depth, each meeting has facilitated the
exchange of information on general developments
on the misuse of drugs. Members have been
pleased to share information with one another on
legislative and other developments in their
countries, on new research findings and on
emerging trends in drug misuse.
The December 2005 ministerial meeting also
allowed members to examine the work which the
Council has taken forward since it last met in
November 2004: 
■ In March 2005, Wales hosted a meeting in
Cardiff, which focused on the issues involved
in producing guidance on undertaking
confidential enquiries into drug-related deaths.
■ Scotland hosted a meeting in Edinburgh on
the topic of children of substance misusing
parents in May.
■ In June, Guernsey hosted a meeting on the
topic of interventions with young people,
including formal and informal education
projects.
■ In November, the Isle of Man hosted a
meeting focusing on arrest-referral schemes. 
It was agreed that ministers would meet again late
in 2006 to review progress. (Brigid Pike)
For further information on the British–Irish Council,
visit www.britishirishcouncil.org
British–Irish Council: Misuse of Drugs
Sectoral Group decides 2006 programme 
Hyper – a voice for young people affected
by drugs
Issue eleven of the magazine Hyper was recently
published by Soilse, a Health Service Executive
Addiction Rehabilitation and Training Centre in
Dublin's north inner city. Participants in Soilse
seeking to move beyond their experiences of drug
misuse produce the magazine. A total of 17
participants contributed to the current issue, with
personal biographical sketches from their
experiences of drug misuse and recovery. Feature
articles include an examination of the implications
of solvent misuse, a personal account of living with
HIV, and a piece about the challenges and pitfalls
of the early days in recovery from drug misuse.
Personal stories include an account of coming off
methadone, surviving a suicide attempt, a
reflection on life's journey and a thoughtful letter
written by one participant to himself, to be
opened in twenty years’ time. A short account of
living with addiction, told through the eyes of a
family member, and a profile of an innovative
peer-education project in Dublin's north inner city
are also given coverage. Information on where to
contact drug treatment centres, including needle
exchanges, is provided. 
Hyper was formally launched following an
evaluation of the pilot phase in 2000. The
evaluation by Donoghue (2000)1 reported that
service users and staff were enthusiastic about the
initiative, with service users reporting that working
on the production of the magazine held many
benefits for them and was a key activity in their
overall programme of recovery. Participants
expressed a deep sense of pride in having their
work published and read by other interested
parties. It was felt that the magazine could serve as
a vehicle of status enhancement for participants in
the eyes of their families and communities. Hyper
won the Total Publishing Award 2002 (UK) for
design innovation of the year. (Martin Keane)
1. Donoghue B (2000) Hyper: A report on the pilot 
phase of the programme. Dublin: Soilse,
Northern Area Health Board. 
Copies of Hyper can be obtained from Soilse, at 01
8724535 or soilsehyper@eircom.net
The complete series is available in hard copy in the
National Documentation Centre on Drug Use.
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Drug-related public nuisance, although not a new
phenomenon, is one which is attracting increased
attention across the EU according to a report published
by the EMCDDA as part of its annual report for 2005.1
In a special focus on the topic ‘Drug-related public
nuisance – trends in policy and preventive measures’,
the EMCDDA highlights the elusive nature of the topic.
Drug-related public nuisance is recognised as a catch-all
concept relating to a range of deviant behaviours, from
crimes to breaches of social norms and values, from
minor acts of deviance to activities which can cause
extreme distress and misery to people.
Identifying a common definition is further
complicated as perception of public nuisance is
influenced by levels of societal tolerance for certain
behaviours. Also, feelings of fear and insecurity are
not strictly proportional to objectively established
levels of criminality and nuisance. For example,
although most countries report significantly higher
levels of public harms associated with alcohol,
concerns about alcohol are eclipsed by perceptions of
a drug problem. The media is identified as having a
significant influence in forming and distorting public
perceptions in this respect.
The most commonly reported drug-related nuisance
activities include public drug taking; public injecting;
obvious drug-related intoxication; street dealing and
crime committed under the influence of drugs;
discarded injecting equipment; open drug scenes;
vulnerability of children to addicts and drug dealers
and intrusive verbal exchanges with drug users and
dealers. The report also considers the genesis of drug-
related nuisance throughout the EU and the strengths
and weaknesses of different methods of measuring its
incidence and societal impact. The various legislative
and policy responses are also considered. General
public order legislation is the key approach to drug-
related public nuisance taken by many countries. The
elimination of open drug scenes also receives a lot 
of attention.
Many of the responses to drug-related nuisance share
common characteristics. Integrated, inter-agency
approaches incorporate prevention, repression and
assistance to drug users. Underlying such approaches is
the notion that, as the problem of nuisance includes so
many different types of behaviour, the range of
responses must be equally broad. Equally important is
the recognition of the importance of grounding
solutions in the local community. Consequently, many
responses are steered by, or established in collaboration
with, local community groups.
An interesting finding of the report is that, although
harm-reduction initiatives such as drop-in centres,
needle-exchange schemes and drug consumption
rooms are often perceived as contributing to the causes
of public nuisance and are opposed on those grounds,
in some countries they have been introduced to
counter such issues – and with some success. Despite
initial resistance to such harm-reduction initiatives in
many countries, the report states that such resistance ‘is
often followed by a normalisation in the relationships
between the community and the professionals involved.
The reason for this change in attitude may be linked to
the fact that such interventions contribute to the
reduction of public nuisance in the area in which they
are located’ (p. 19).
The indicators used to measure the level of success of
interventions include opinion polls, victim surveys
and ethnographic studies, although it is reported that
‘comprehensive and overarching evaluations of an
entire public nuisance policy or strategy, even in
countries which have such a strategy, are quite rare’ 
(p. 21).
Although drug-related nuisance is not a new
phenomenon, what may be new is the growing
concern about it nationally and internationally. The
question is raised as to whether this reflects a change in
the incidence of the phenomenon, or a lessening of
tolerance. With regard to the latter, the report raises a
note of caution and suggests that concerns as to
community security rights must be balanced against
individual rights.
The diversity of approaches taken in response to drug-
related public nuisance may, it is suggested, reflect the
shapelessness of its definition. It is concluded therefore
that further conceptual work is required, particularly
with regard to establishing a common definition of the
phenomenon. In conclusion, the report identifies a
general shift in emphasis of EU national drug control
policies away from simply reducing use of drugs to
targeting drug-related behaviours that impact
negatively on the community. Similarly, it also identifies
a growing interest in links between drugs and driving
and the use of drugs in the workplace. The report
identifies a trend throughout the EU which de-
emphasises criminal punishment of the individual user,
specially for simple possession of drugs for personal use:
‘It appears as if criminal sanctions have been reduced
(particularly imprisonment) for the individual user in a
private setting but increased for behaviours and
situations that are public or that may affect community
or society as a whole’. (Johnny Connolly)
1. European Monitoring Centre for Drugs and Drug
Addiction (2005) Annual report 2005: selected
issues. Luxembourg: Office for Official Publications
of the European Communities.
A copy of the EMCDDA annual report for 2005 can
be obtained from the National Documentation
Centre on Drug Use. An electronic copy of the Irish
submission, 2005 National Report (2004 data) to the
EMCDDA by the Reitox National Focal Point, Ireland:
new developments, trends and in-depth information on
selected issues, is available on the Drugs in Ireland
section of the NDC website.  
Responding to drug-related public
nuisance
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Targeting offending problem drug users in
the EU
The EMCDDA annual report 2005 includes a special
issue on the use throughout the EU of alternatives
sanctions to prison involving a drug treatment
component, as a response to drug-related crime.1
The EMCDDA identifies a broad consensus among
member states that prison is a detrimental
environment for people whose offending is related
to a drug addiction. Prisons are overcrowded in
many countries and drugs are often widely
available within prison, rendering recovery from
addiction extremely difficult. Treatment in the
community often offers a greater potential to
improve people’s health and well-being. Also, the
high cost of imprisonment relative to community-
based sanctions and the potential of drug
treatment in the community to have a greater
impact on offending behaviour are key reasons for
the development of alternative sanctions.
The EU Drugs Action Plan 2005–2008 asks member
states to ‘make effective use and develop further
alternatives to prison for drug abusers’.2 In Ireland,
numerous policy documents have advocated the
need to develop alternatives to imprisonment and
to use prison as a last resort.3 The Children Act
2001 sets out a number of general principles
biased towards rehabilitation and the
discouragement of custody for child offenders. In a
recent survey of public perceptions of crime in
Ireland, nearly three-quarters (73%) of respondents
believed that non-custodial sanctions, such as fines
and community service, would be more fitting
than custodial sanctions for certain crimes.4
In most countries, problem drug users usually
undergo treatment in residential drug-free
treatment centres as an alternative to prison. 
A number of out-patient treatment programmes
combined with a regulatory system such as drug-
testing or electronic surveillance are also identified. 
A question which arises in the context of so-called
alternatives relates to the concept of net-widening,
whereby the ‘number of people falling under the
supervision of the criminal justice system has
increased, often without reducing the number of
drug users in prison’ (p. 29). The EMCDDA also
points out that ‘it is not always clear from the data
whether the alternatives are applied to problem
drug users, or to recreational users "encouraged"
to take counselling’ (p. 29). According to a report
on the Irish Probation and Welfare Service
prepared by the Comptroller and Auditor General,
the estimated total number of persons under
supervision increased by half between 1995 and
2002, and there was a similar increase in the
prison population.5 It appears therefore that,
despite the broad political and public consensus
supporting it, there has been little if any increase
in the use of alternatives to prison relative to
custodial sanctions between 1995 and 2002. 
The EMCDDA reports that no comprehensive
major national or European studies are available to
evaluate treatment as an alternative to
imprisonment. Research, it is concluded, is still too
scarce and too disparate to establish what works,
how, when and for whom. However, a number of
lessons arising from experience to date are
identified in the report. These can serve as useful
guidelines upon which future initiatives can build.
These include the following:
■ Legislation must be implemented in a manner
that benefits both the drug user and society.
■ Knowledge about legal possibilities and their
implementation and about the drug-related
treatment options available is required of
police, prosecution and judges.
■ Trust, co-operation and co-ordination
between criminal justice, health and social
service systems are essential if alternatives are
to be effective. Much is needed in terms of
attitudes, knowledge and practical
management to facilitate resource-saving co-
operation and co-ordination.
■ The route into treatment is an important
indicator in predicting success. Studies have
found that rates of relapse into criminality
vary significantly between drug users who
start treatment before having contact with
prison and those who enrol in treatment after
some time in prison, with evidence that
retention rates are higher for those who move
straight to treatment following sentencing.
Treatment seems to work best if the addict is
motivated and is actively and intensively
approached and advised to undergo
treatment. There must be good non-
bureaucratic management and a reduction of
waiting times.
■ Treatment services often lack sufficient
resources, particularly for young people. The
possibilities identified for drug treatment have
increased the workload of the treatment
services and this has led to delays in accessing
services in some countries, and in others a
‘partial breakdown in the capacity of such
services’ (p. 29).
■ Treatment potential is improved if care
facilities follow clinical standards and have
enough and qualified staff. Treatment staff
must counter prejudice against clients
referred from the criminal justice system. Staff
must have sufficient training to work with
such clients and keep them motivated.
Treatment should be adapted to clients’
needs. There must be effective monitoring
and aftercare.
■ There must be a feeling of a real threat of
punishment. There needs to be good co-
operation with local authorities to encourage
reintegration in the community.
Treatment-based alternatives to
imprisonment
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Treatment-based alternatives to imprisonment (continued)
The main findings of the evaluation of the Irish
drug court indicated that, although a number of
participants continued to offend while in the
programme, the rate at which participants were
arrested, charged and had their bail revoked
declined the longer they were in the programme.6
Similarly, a key finding of this report and of a great
deal of the literature in this area is that retention in
treatment is a crucial indicator of success. (Johnny
Connolly)
1. European Monitoring Centre for Drugs and
Drug Addiction (2005) Annual report 2005:
selected issues. Luxembourg: Office for Official
Publications of the European Communities.
2. European Commission (2005) EU Drugs Action
Plan 2005–2008. Official Journal, C 168,
08/07/2005 p. 0001–0018. 
3. Drug Misuse Research Division (2004) 2004
National Report to the EMCDDA by the Reitox
National Focal Point: Ireland; new developments,
trends and in-depth information on selected issues.
Dublin: Health Research Board.
4. McDade P (1999) Public perception of crime in
Ireland. Templemore, Co Tipperary: Garda
Research Unit.
5. Comptroller and Auditor General (2004) Report
on value for money examination of the Probation
and Welfare Service. Dublin: Department of
Justice, Equality and Law Reform.
6. Farrell M (2002) Final evaluation of the pilot drug
court. Dublin: Courts Service.
The first training seminar in Ireland in the use of
buprenorphine by general practitioners for opiate-
dependent patients was held at the Irish College of
General Practitioners on 23 November 2005. 
Participants included the general practitioner co-
ordinators and liaison pharmacists from the Health
Service Executive drug services, as well as a small
number of general practitioners and pharmacists
who are preparing to use buprenorphine for
selected patients in the primary care setting. Two
experts from the Royal College of General
Practitioners (RCGP) in London facilitated the
seminar. 
According to the Irish College of General
Practitioners, after the introduction of
buprenorphine on a pilot basis in the primary care
setting, best practice guidelines will be developed
for the Irish context and, following that, further
training will be provided to Level 2 general
practitioners. Plans are now being progressed for
the development of a pilot programme with a
small group of interested general practitioners and
pharmacists. During this pilot programme, the
RCGP publication, Guidance for the use of
buprenorphine for the treatment of opioid
dependence in primary care,1 will be used until
experience is gained in the context of primary care
in Ireland.
The National Medicines Information Centre
conducted a review of the use of buprenorphine as
an intervention in the treatment of opiate
dependence syndrome.2 This examined the
effectiveness of buprenorphine as a treatment
option, its safety in use, as well as the practical and
pharmaco-economic considerations associated
with its use. Where appropriate, the authors
compared the treatment outcomes, safety issues
and costs to those of methadone – the mainstay of
treatment for opiate dependence in Ireland. The
methods employed in this analysis were: literature
reviews, systematic reviews, case histories and an
economic evaluation. 
The key findings of the review were:
■ In terms of its use in managed withdrawal,
the studies were too heterogeneous to enable
formal meta-analysis, but a systematic review
suggested that buprenorphine had potential
in this area. 
■ The results of a formal meta-analysis on its
use in treatment as an opiate substitute
using six-randomised controlled trials, with
methadone as comparator, showed that high-
dose buprenorphine was similar to high-dose
methadone in terms of treatment retention,
with a small increase in positive urinalysis
relative to methadone. Although the latter
was statistically significant, it was not felt to
be clinically relevant. It was not possible, from
the data, to determine the optimal dosing
regimen, although it was noted that less than
daily dosing was feasible in clinical practice.
■ From the data available, it was not possible to
determine whether buprenorphine was more
suitable for specific sub-groups. There is some
evidence to suggest that those with higher
psychosocial and global functioning are more
likely to respond to buprenorphine, but more
studies are required to substantiate this.
■ Data available to date on its use in pregnant
women showed that buprenorphine was
efficacious and safe for both the woman and
the foetus, but definitive recommendations
Buprenorphine – increasing choice for
patients and doctors
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on dosing regimens could not be deduced
from the results of studies undertaken.
■ The safety data available to date suggest that
buprenorphine has a known and predictable
toxicity profile, related to its opioid agonist
pharmacology and its interactions with other
medicines. Although causality has not been
proven, there is a warning regarding possible
hepatotoxicity associated with its use and it is
recommended that liver function tests are
regularly performed for patients receiving
buprenorphine. The biggest problem to date
appears to be the risk of interaction with
alcohol or benzodiazepines. 
■ The results from the pharmaco-economic
evaluation show that use of buprenorphine
appears to be less cost-effective than the
current methadone system. It may prove to
be a cost-effective treatment option in
selected Irish settings (such as general
practice), but further studies are needed to
identify these settings.
■ Buprenorphine has a known potential for
abuse, because of its opioid effects. Studies
from France suggest that abuse may occur in
up to 30% of treatment subjects. Research
findings indicate that abuse is more likely in
those subjects not closely supervised by either
a physician or a dispensing pharmacist. 
In Ireland, buprenorphine (mainly Temgesic) misuse
among the treated population is rare. Of the 44,767
cases reported to the National Drug Treatment
Reporting System (NDTRS) between 1998 and
2003, 56 (0.1%) reported that buprenorphine was a
problem drug. Between 1998 and 2003, the
number of cases reporting buprenorphine as a
problem drug decreased considerably, from 18 in
1998 to 5 in 2003 (Table 1). 
There are no data available on buprenorphine-
related deaths in Ireland. 
In August 2002, the Irish Medicines Board
authorised the use of Subutex (a buprenorphine
preparation specifically for treatment of opiate
dependence) in Ireland.2 The licence for the use of
Subutex in opiate dependency was amended in
November 2005, and states 
Treatment with SUBUTEX sublingual tablets must
be by physicians who have specialist training in
its use and all treated patients must be on a
central register according to Drug Misuse
Programme guidelines. These physicians can be
consultants, and/or Level I or Level II GPs who
have received special training. All patients will be
reviewed and reassessed regularly.3
In order for this programme be operationalised, a
system similar to that existing for methadone,
including a protocol and a central register, needs
to be established. This is an opportunity to provide
choice of treatment to problem opiate users as
well as to identify which substitute is most suitable
for different sub-groups of patients. (Jean Long)
1. Ford C, Morton S, Lintzeris N, Bury J and
Gerada C (2004) Guidance for the use of
buprenorphine for the treatment of opioid
dependence in primary care. 2nd edition.
London: Royal College of General Practitioners.
2. National Medicines Information Centre (2002)
Report to the National Advisory Committee on
Drugs on use of buprenorphine as an intervention
in the treatment of opiate dependence syndrome.
Dublin: Stationery Office.
3. Quoted from manufacturer’s Summary of 
Product Characteristics, November 2005, as
listed by the Irish Pharmaceutical Healthcare
Association on IPHA Medicines Compendium
Online (www.medicines.ie).  
Buprenorphine – increasing choice for patients and doctors
(continued)
Table 1  Number (%) of treated cases reporting problem buprenorphine use and
reported to the NDTRS, 1998–2002
Treatment status 1998 1999 2000 2001 2002 2003
Number (%)
All cases 6048 6206 6933 7900 8596 9084
Cases reporting problem 
buprenorphine use 18 (0.3) 18 (0.3) 10 (0.1) 3 (0.0) 2 (0.0) 5 (0.1)
Source: Unpublished data from the NDTRS
In Ireland,
buprenorphine
(mainly Temgesic)
misuse among
the treated
population is
rare.
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Welcome to the fourteenth EDDRA (Exchange on
Drug Demand Reduction Action) column. The aim
of this column is to inform people about the
EDDRA online database, which exists to provide
information on good practice interventions to
policy makers and those working in the drugs area
across Europe, and to promote the role of
evaluation in reducing demand for drugs. The
database is co-ordinated by the European
Monitoring Centre for Drugs and Drug Addiction
(EMCDDA). 
During 2005 a total of 10 additional interventions
from Ireland were added to the EDDRA database
(Table 1). These interventions were selected on the
basis that they were well designed and contained
an evaluation component and quality-control
criteria laid down by the EMCDDA. 
The EDDRA column
Table 1   Ten interventions added to the EDDRA database in 2005
Area of intervention Project Primary aim
Vocational  FÁS Community Employment Assist participants to progress to labour
reintegration Scheme for drug users market activity
Social reintegration Blanchardstown EQUAL Enhance opportunities for current and former 
Inter-agency Initiative drug users from Blanchardstown to progress 
towards labour market opportunities
Universal school-  Smoke-Free Leitrim: A smoking- Reduce cigarette smoking among young
based prevention prevention and education people in County Leitrim
programme
Universal school-  North Eastern Health Board (now Create a smoke-free environment in the HSE
based prevention HSE North Eastern Region) cigarette North Eastern Region
smoking cessation programme
Universal family-  CAD Parenting for Prevention Promote the role of parents and carers in 
based prevention educing demand for drugs
Selective community- Young People’s Facilities and Attract at-risk young people in disadvantaged
based prevention Services Fund (YPFSF) areas into sporting and diversionary activities 
Prevention/ ICON Drug Support Service Provide support, emergency care and 
Information practical help to local drug users and their 
families
Prevention/ Certificate in Addiction Studies Provide quality drug education, training and 
Information support that will enhance the competencies 
and capacities of staff in a variety of settings 
and sectors
Community-based Mountview/Blakestown Provide a quality professional service to 
treatment and   Community Drug Team support drug users, their families and the
harm reduction community in moving towards a drug-free 
experience
Criminal justice The BOND Project Support the reintegration of young people 
(Blanchardstown Offenders leaving prison or place of detention by 
for New Directions) directing them into appropriate supports in 
the community
Table 2  The five highest-contributing EU
countries to EDDRA database,
February 2006 
Country Number of entries
Austria 65
Spain 63
Germany 60
Ireland 56
Greece 49
If you have an exciting and innovative
intervention and would like to share your
information with professionals throughout
the EU, why don't you consider submitting
your work for inclusion on the EDDRA
database? Contact EDDRA Manager, Martin
Keane, at the Drug Misuse Research Division,
Health Research Board, Knockmaun House,
42–47 Lower Mount Street. Dublin 2.  
Tel: 01 676 1176 ext 169, or 
Email: mkeane@hrb.ie
Ireland is consistently one of the largest contributors to the EDDRA database, with 56 interventions included
up to February 2006 (Table 2).  The database contains an overall total of 576 interventions. (Martin Keane)
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The move to Knockmaun House comes just over three years
after the NDC first opened in Holles Street. The extra space in
our new premises will allow the NDC to expand its library
collection, accommodate a greater number of visitors and
increase the range of services it provides. 
Background
The need to establish a collection of research documentation
dealing with the issue of drugs in Ireland was acknowledged in
the report of the Interim Advisory Committee on Drugs (2000).
The report recommended the establishment of an information
resource on drug use which would ensure that Irish research
and policy-related publications would be accessible and easily
retrieved by policy makers, service providers, community
groups and the interested public. Demonstrating vision and an
awareness of the possibilities created by digital technology, the
Committee further recommended that an electronic library of
Irish research in the drugs area be created and that this should
be made available online.
The report emphasised the need to build on existing resources.
Consequently, the Drug Misuse Research Division (DMRD) of
the Health Research Board (HRB) was identified as the most
appropriate agent to develop this information resource. In
December 2002 the HRB launched the NDC website and
opened a special library devoted to literature on drugs in its
offices in Holles Street in Dublin and the electronic library of
Irish drugs research became publicly available. 
Technical development
In order to create an electronic library of drugs research, the
NDC developed a new content-management system in
collaboration with a software development company, iMaxan.
This system is entirely web-based and staff can create and
publish records from any computer with an Internet connection.
A copy of the Alcohol and Other Drugs Thesaurus (NIAAA, 2000)
was created and integrated into the cataloguing system,
providing the database with an excellent indexing tool. The
integrated nature and flexibility of the new system was an
important factor in negotiating permission for access to
restricted documents, such as journal articles and book chapters. 
Current information resources
Anybody with an interest in drug use in Ireland can, by
searching the electronic library, quickly establish what research
has been carried out and what policy documents have been
published,  and can then have almost immediate access to
documents of particular interest. Researchers can use the same
source for all studies of the drug situation in Ireland, whether
from a sociological, psychological, legal or medical perspective.
Other online resources include a special news page and a
directory of current research. 
The new NDC library in Knockmaun House holds a special
collection of drug-related literature, providing an invaluable
guide to the most recent research and thinking on all aspects of
substance use and addiction, including treatment, education,
prevention and legal matters. This library is open to the public
and anybody can drop in and avail of its services. The library
collection includes: over 3,000 books, reports and conference
papers; 16 specialist drug-related periodicals; and a range other
peer-reviewed health, epidemiological and medical journals.
Visitors can also make use of a number of online bibliographic
databases covering the fields of heath, psychology and the
social sciences. 
Use of NDC resources
The resources described above became publicly available at the
end of 2002. Since the NDC website was launched and the
library opened, both the level of use of services and the number
of people using NDC resources have steadily increased. The
NDC takes considerable care to record all use of its resources.
During 2005 the website had 16,480 unique visitors and the
library dealt with over 1,500 queries.
Future developments
The NDC is currently working on a number of projects which,
when completed, will expand the range of services provided
and add value to its own collections. New developments
include a series of fact sheets on a number of drug-related
topics as they relate to the situation in Ireland, a directory of
education and training courses and an e-learning module which
allows users make more effective use of the electronic library
and other online resources. (Brian Galvin)
NDC opening hours: 9.30 – 4.45 pm, Monday to Friday; 
late opening on Thursday by appointment.
To contact NDC: Tel (01) 676 1176; Email ndc@hrb.ie
The National Documentation Centre on Drug Use
is funded by the Department of Community, Rural
and Gaeltacht Affairs under the National
Development Plan 2000–2006.
The National Documentation Centre on Drug Use
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NDC staff look happy with the move
Increase in use of NDC resources 2003-2005
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On 18 November 2005 the Irish Society for the
Prevention of Cruelty to Children (ISPCC) launched its
three years of statistics for the Schoolmate Drug and
Alcohol pilot prevention scheme. This pilot scheme,
launched in 2003, provides a direct-access support service
to vulnerable young people who are at risk of early
school-leaving due to drug and substance abuse.
www.ispcc.ie 
On 16 December 2005 The SPHE story: an example of
incremental change in the school setting was launched by
the Minister for Education and Science, Mary Hanafin TD.
This Report was prepared by the Social, Personal and
Health Education (SPHE) Support Service based in Marino
Institute of Education in Dublin. It deals with the
implementation of the SPHE curriculum, which includes a
module on substance abuse, at junior cycle post-primary
level, drawing on material from three evaluations
commissioned by the Support Service and tracing
progress between 2000 and 2003. The report notes that
the main challenges to successful implementation of SPHE
at school level are the continuing professional
development needs of teachers, and the need to establish
time for SPHE in a crowded curriculum and to co-ordinate
the programme in schools. Minister Hanafin called for a
‘supportive school environment’, underpinned by school
policies on substance use, bullying and the school’s code
of behaviour. www.education.ie 
In December 2005 the report Moving beyond educational
disadvantage was published. Prepared by the Educational
Disadvantage Committee (set up by the Minister for
Education in April 2002 under section 32 of the Education
Act 1998, ‘to advise the Minister on policies and strategies
to be adopted to identify and correct educational
Disadvantage’), the report sets out guidelines for effective
services to address educational disadvantage, envisages
the way forward in developing an integrated approach to
educational inclusion and equality and concludes with a
strategy for an inclusive, diverse and dynamic learning
society without barriers. It suggests that educational
equality will only be achieved within the broader context
of achieving social inclusion, and argues that poverty and
other issues that contribute to educational disadvantage,
such as drug and alcohol abuse, must be tackled in
parallel and in an integrated way. www.education.ie 
Between 9 November and 1 December 2005 the
National Action Plan against Poverty and Social
Exclusion 2006–2008 was the subject of a series of seven
regional seminars hosted by the Office for Social Inclusion
(OSI). This Plan is due for completion in September 2006.
Suggestions in relation to the problems associated with
drug and alcohol misuse included identifying drug users
as a vulnerable group within the Plan; providing
additional services for homeless people, including more
wet hostels for people misusing drugs or alcohol;
improving drug and alcohol rehabilitation services;
developing an active, outreach health promotion strategy,
together with more community-based counselling and
therapeutic services to address the problems of suicide
and substance misuse in rural and urban areas. With
regard to anti-social behaviour, much of which was seen
as arising from substance or alcohol abuse, suggestions
included developing both security-led and social
responses, and committing to implementation of the
National Drugs Strategy, which should focus on
responding to emerging needs in rural and urban areas.
www.socialinclusion.ie 
On 20 January 2006 the Drug Treatment Centre Board
became the first clinical laboratory in Ireland (funded by
the Health Service Executive) to be accredited to the IS0
17025 standard. It is a formal recognition that the
laboratory has competent staff, appropriate testing
equipment and suitable laboratories and that it carries out
its work according to international standards.
www.addictionireland.ie 
On 24 January 2006 A vision for change: the report of the
Expert Group on Mental Health Policy was launched by
Mary Harney, Tánaiste and Minister for Health and
Children. The report describes a framework for building
and fostering positive mental health across the entire
community and for providing accessible, community-
based, specialist services for people with mental illness. In
relation to mental health services for persons with co-
morbid mental illness and substance abuse problems, the
report recommends:
■ The proposed general adult Community Mental
Health Teams (CMHTs) should cater for adults who
have co-morbid substance abuse and mental health
problems, particularly when the primary problem is a
mental health problem.
■ A national policy co-ordinator should be appointed
to deliver national objectives and standards
pertaining to primary care and community
interventions for drug and alcohol abuse and their
linkage to mental health services.
■ Specialist adult CMHTs should be developed in each
catchment area of 300,000 people to manage
complex, severe substance abuse and mental
disorder.
■ Two additional adolescent multidisciplinary CMHTs
should be established (in addition to the two in
Dublin) to provide expertise to care for adolescents
with co-morbid addiction and mental health
problems.  www.dohc.ie 
On 26 and 27 January 2006 Drugs and Civil Society in
Europe was the theme of a meeting in Brussels attended
by more than 100 representatives of Europe’s civil society.
The meeting was organised by the Directorate-General for
Freedom, Security and Justice of the European
Commission in pursuit of the objective in the EU Drugs
Action Plan (2005–2008) ‘to strengthen the involvement
of civil society in EU drugs policy planning and
implementation’. The main outcome of the meeting was
the recognition by all sides that a permanent and properly
resourced forum is needed to enable the EU institutions
and civil society to communicate in such a way that grass-
roots experience can feed into EU policy-making on drugs.
The Commission will take this matter up in its Green
Paper on Drugs and Civil Society, expected to be
published later in 2006. www.europa.eu.int 
(Compiled by Brigid Pike)
In brief
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From Drugnet Europe
New French study on drugs and driving
Cited from Cécile Martel Drugnet Europe No. 53, 
January–March 2006
In November 2005, a French study on the issue of
drugs and driving was published in the British
Medical Journal. The purpose of the study was to
evaluate the relative risk of being responsible for a
fatal car crash while driving under the influence of
cannabis. …The study concludes that the risk of
being responsible for a fatal car accident increases
threefold when driving under the influence of
cannabis. However, it reveals that the proportion
of fatal car crashes attributable to cannabis use is
significantly lower (2.5%) than that associated with
alcohol (28.6%). 
Driving under the influence of psychoactive
substances is a hot topic in many EU Member
States. The European Union drugs action plan
(2005–2008) also stresses the crucial importance of
undertaking work related to driving under the
influence of alcohol, drugs and medicines. In
November 2003, the Council of the European
Union adopted a Resolution on combating the
impact of psychoactive substance use on road
accidents. Meanwhile the EMCDDA is
collaborating with the Pompidou Group of the
Council of Europe and will update its legal report
on this issue in the coming months. Finally, the
EMCDDA will also publish a selected issue on
drugs and driving in its annual report 2007.
International meeting on drugs and driving
Cited from Linda Montanari and Alain Verstraete
Drugnet Europe No. 53, January–March 2006
A conference focusing on the evaluation of
instruments for testing those driving under the
influence of drugs was held in Baltimore, USA 
from 5–6 December. Attended by some 50
professionals from Europe and the USA, the
meeting was organised by the Walsh Group
(www.walshgroup.org) with the support of the
National Institute on Drug Abuse (NIDA)
(http://www.nida.nih.gov/). It presented findings
from the Rosita-2 project. Results highlighted
related to: an analysis of the sensitivity and
specificity of several roadside tests; an evaluation of
different drug-testing instruments; and a
comparison of oral fluid tests versus blood analysis.
Rosita-2, a study on roadside drug testing
Cited from Alain Verstraete Drugnet Europe No. 53,
January–March 2006
Rosita-2 (RoadSide Testing Assessment) is a joint
EU–US project designed to evaluate on-site roadside
drug-testing devices (http://www.rosita.org). ...the
study aims to evaluate the performance of 10
different saliva-based testing devices. In comparison
with the results of Rosita-1, carried out five years
ago, the findings from Rosita-2 show an
improvement in the reliability of the devices and a
more acceptable level of specificity of the devices
(i.e. few false positive results were recorded). On
the downside, 30% or more of the devices tested
failed to give any result. Sensitivity to cannabis was
particularly poor. …The final results of the project
will be submitted to the European Commission in
March 2006.
Drugnet Europe is the quarterly newsletter of the
European Monitoring Centre for Drugs and
Drug Addiction (EMCDDA). An electronic
version of Drugnet Europe is available on the
EMCDDA website at www.emcdda.eu.int
If you would like to receive a hard copy of
the current or future issues of Drugnet
Europe, please contact Charlene Lydon, Drug
Misuse Research Division, Health Research
Board, Knockmaun House, 42–47 Lower
Mount Street, Dublin 2. Tel: 01 676 1176 ext
127; Email: dmrd@hrb.ie
Recent publications
Books
Occasional and controlled heroin use: not a
problem?
Warburton H, Turnbull P and Hough M
Joseph Rowntree Foundation 2005, 73 pp.
ISBN 1 85935 424 6
Little is currently known about groups of
occasional and controlled heroin users. This study,
conducted by the Institute for Criminal Policy
Research, aims to improve our understanding
about patterns of heroin use, the nature of
dependence and ways of controlling it. The study
explores the patterns of heroin use among a
population of non-dependent and controlled
dependent heroin users who saw their use as
relatively problem free. The report describes how
this largely hidden population maintained stable
and controlled patterns of heroin use. It examines
reasons for starting to use heroin, pervious and
current patterns of use, mechanisms and factors
that helped to control use, and why this group
saw their use as fairly problem free. The report
draws on a series of in-depth qualitative interviews
with heroin users and on an internet survey.  
Heroin is a dangerous drug. It can have a
devastating impact on individual lives, on users’
families and on the wider community. However, as
the report shows, some people, in some
circumstances, can effectively manage and regulate
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their use. This raises important issues for
treatment. Can dependent and chaotic heroin
users learn from the experience of this group?
Should controlled heroin use be regarded as an
acceptable short- or middle-term goal for clients of
drug treatment services? Should popular beliefs
about the inherent uncontrollability of heroin
dependence be left unchallenged? The report
deconstructs some of the myths surrounding
heroin use and heroin dependence. It is relevant to
policy-makers, those working in the drug
treatment field, academics and drug researchers.
Random drug testing of schoolchildren: a shot
in the arm or a shot in the foot for drug
prevention?
McKeganey N  
Joseph Rowntree Foundation 2005, 24 pp.
ISBN 1 85935 282 0
The idea of randomly drug testing UK
schoolchildren to see if they have used illegal
drugs has received supportive comments from
across the political spectrum. But is school-based
random drug testing a development that should
be welcomed, or is it something we should seek 
to avoid? 
This report deals with the theory, the evidence,
and the ethics of random drug testing of UK
pupils. It reviews current literature on all aspects of
the issue and considers evidence in support of
drug testing, including experience in the US,
where random drug testing is commonplace. It
asks whether such testing is in accordance with
human rights legislation and the rights of the
child. Alongside such ethical issues, it reviews
practical questions as to the feasibility of testing
pupils in UK schools, as well as concerns as to the
way in which such testing programmes may
fundamentally alter children’s experience of school.
The author finds that such programmes, while they
may help some pupils, may harm others. For this
reason the report concludes that before random
drug testing programmes are widely developed in
UK schools this initiative should be subjected to
rigorous and independent evaluation. This report
will be of interest to teachers, parents, young
people and anyone else working in the field of
drug prevention.
Understanding drug selling in communities:
insider or outsider trading?
May T, Duffy M, Few B and Hough M
Joseph Rowntree Foundation 2005, 56 pp.
ISBN 1 85935 417 3
To date, little research has been carried out in this
area and knowledge is slight about how local drug
markets actually operate. This report, by the
Institute for Criminal Policy Research at King’s
College London, describes how people become
involved in selling drugs, and their attitudes
towards their dealing. It describes the impact of
drug dealing and dealers on communities in which
they operate, and the nature of the relationship
between them. It also documents the complex
relationships that some communities have with
their illicit economies and suggests that preventive
work needs to acknowledge the ambivalence that
communities in deprived areas may have towards
drug markets and markets for stolen goods.
The authors conclude that enforcement activity is
an essential component for tackling drug dealing.
However, they argue that if policies are to have
anything more than a short-term impact, other
agencies besides the police will have to shoulder
some of the responsibility. This publication will be
of interest to politicians, central and local
government officials, police managers, drug
workers, academics and drug researchers. 
Journal articles
The following abstracts are from a selection of
articles relating to the drugs situation in Ireland
recently published in international journals.
The Irish drinking habits of 2002: drinking and
drinking-related harm in a European
comparative perspective
Ramstedt M and Hope A  
Journal of Substance Use 2005; 10(5): 273–283
This article aimed to examine drinking habits and
experiences of adverse consequences of drinking
among men and women in Ireland 2002 and to
compare some results with earlier European studies
using similar data and methods.  Data on self-
reported drinking habits and experiences of alcohol-
related problems were obtained from a general
population survey undertaken in 2002. Two
approaches were used: (1) cross-tabulations of
drinking habits and the experience of adverse
consequences in various demographic groups (2)
logistic regressions predicting the likelihood of
experiencing problems.  Self-reported alcohol
consumption confirms statistics on alcohol sales; a
lot of alcohol is consumed in Ireland today, despite
a large fraction of abstainers in the population.
Binge drinking is very common, and, out of 100
drinking events, 58 end up in binge drinking for
men and 30 for women. Irish drinkers also
experience harmful drinking-related consequences
to a larger extent than in other western European
countries. Both volume of drinking and binge
drinking affect the likelihood of experiencing most
alcohol-related harms. The article concludes that
drinkers in Ireland drink more than those in other
western European countries and many have risky
drinking habits that lead to adverse consequences. It
will be an important challenge to find preventive
measures that can reduce these problems in Ireland.
Recent publications (continued)
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Cocaine dependence and attention switching within and
between verbal and visuospatial working memory
Kubler A, Murphy K and Garavan H
European Journal of Neuroscience 2005; 21(7): 1984–1992
Many studies have shown the negative effects of cocaine on
neuropsychological and cognitive performance in drug-dependent
individuals, but little is known about the underlying neuroanatomy of
these dysfunctions. The present study addressed attention switching
between items held in working memory (WM) with a task in which
subjects were required to store and update two items held in verbal or
visuospatial WM. Attention-switching frequency varied between trials,
thereby allowing us to isolate the switching component of task
performance. Behavioural data revealed that cocaine addicts
performed worse than healthy controls in all tasks. On the visuospatial
task addicts performed at chance levels, revealing particular
impairment in visuospatial WM. On the verbal task, in which controls
and users could be matched for performance, we identified
attenuated responses in prefrontal and cingulate cortices and in striatal
regions, while other areas such as dorsolateral prefrontal cortex did
not differ between healthy controls and users. The results reveal that
addiction may be accompanied by specific rather than ubiquitous
hypoactivation in prefrontal and subcortical areas and suggest a
compromised ability in users to control their attention to their
thoughts as might be particularly relevant when required to switch
away from drug-related thoughts, and thus the dysfunction in
attention switching may contribute to the maintenance of addiction. 
Dying for heroin: the increasing opioid-related mortality in the
Republic of Ireland, 1980–1999
Kelleher MJA, Keown PJ, O'Gara C, Keaney F, Farrell M and Strang J  
European Journal of Public Health 2005; 15(6): 589–592
This study aimed to examine trends in opioid-related mortality over
a 20-year period in Ireland. Retrospective analysis of deaths
attributed to ICD-9 codes 304.0 (morphine-type dependence) and
E850.0 (accidental poisoning by opiates and related narcotics) in
Ireland between 1980 and 1999. Ireland has seen a rapid increase
in the number of opioid-related deaths over the 20-year period
studied, from 0.01% of total deaths in 1980 to 0.15% in 1999. This
is most marked in the younger age groups where, for example, it
rose to 23% of 15–19 year old male deaths for 1997. The opioid-
related mortality rate in the 15–44 years age range increased by
nearly 14 times between 1980–1984 and 1995–1999. Over the
whole period, 87% of opioid-related deaths were amongst males.
Outside Dublin there has been a considerable increase in opioid-
related mortality, nearly doubling the percentage of the total from
6% in the 1980s to 11% in the 1990s. The study concludes that
opioid-related mortality is an increasing problem in Ireland, as in
other Western countries. The spread of opioid-related mortality
outside Dublin to rural and other urban areas will have implications
for service planning and provision.
Drug smuggling using clothing impregnated with cocaine
McDermott S and Power J 
Journal of Forensic Sciences 2005; 50(6): 1423
A case study is presented where a woman travelling from South
America to Ireland was detained at Dublin Airport and articles of
clothing in her luggage were found to be impregnated with
cocaine. The study shows that the amount of powder recovered
from the garments was approximately 14% of the total weight of
the garments. The cocaine was in the form of cocaine
hydrochloride and the purity was approximately 80%. An
examination of the garments under filtered light highlighted the
areas exposed to cocaine and indicated that the method of
impregnation was by pouring liquid containing cocaine onto the
clothing. 
‘An Irish solution to an Irish problem’: harm reduction and
ambiguity in the drug policy of the Republic of Ireland
Butler S and Mayock P 
International Journal of Drug Policy 2005; 16(6): 415–422
This paper traces the gradual introduction, on public health
grounds, of harm-reduction practices and services, such as
methadone maintenance, needle exchange and the creation of
outreach and locally-based services, following the identification in
the mid-1980s of needle-sharing among injecting drug users as one
of the key routes for the transmission of HIV in this country.  
It is argued that harm reduction in Ireland has been largely implicit, in
the sense that political leaders have generally not encouraged or
participated in explicit public debate on this topic, nor have they ever
publicly announced that this concept now underpins much of the
healthcare system's responses to illicit drug use. It is also argued that
this covert style of policy making has persisted, despite the more
recent proliferation of formal policy-making structures and the
dominance of a rhetoric which emphasises strategic management and
the allegedly transparent and evidence-based nature of drug policy.
This tactic of shrouding drug policy in ambiguity is discussed in the
context of the wider tendency within Irish political culture to manage
sensitive and potentially divisive social issues in such a manner.
It is concluded that the ambiguity which surrounds harm reduction
in Ireland has been functional in that it has confused and frustrated
ideological opponents of this concept, but dysfunctional in that it
has not facilitated the emergence of more tolerant or respectful
attitudes towards drug users and may have delayed the
introduction of a wider range of harm reduction practices.
Irish addiction services – past, present and future
Keenan E  
Irish Journal of Psychological Medicine 2005; 22(4): 118–120
A brief overview of the development of addiction services in Ireland
reveals a wide disparity between the treatment of opioid dependence
in the east of the country and the way statutory services deal with the
significant problem of alcohol misuse. The response of the health
services in the early 1990s to the problem of heroin dependence was
largely driven by public health. The growing numbers of injecting
drug users infected with HIV led to the development of a harm
reduction policy, encompassing needle exchange, education for drug
users and methadone maintenance. This current approach to the
treatment of substance misuse however has not been without its
critics. In contrast to the resources provided for the development of
drug services, the provision of resources for alcohol services has been
grossly inadequate. In addition to the recognition of strong links
between addiction services and mental health services, there are a
number of links with other healthcare providers which would benefit
patients. The future development of addiction services requires a
combined drug and alcohol service under the umbrella of mental
health. The success and experience of the drugs service in developing
a community based treatment service involving statutory, community
and voluntary agencies can provide a template for a similar approach
in relation to alcohol services. This should complement and enhance
the implementation of the national alcohol strategy.
Problem drug use and the political economy of urban
restructuring: heroin, class and governance in Dublin
Punch M  
Antipode 2005; 37(4): 754–774 
This paper offers an exploration of problem drug use in the urban
environment, connecting with broader concerns about the progress
and contradictions of city redevelopment and change. The
discussion is situated within some recent theoretical debates about
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the political economy of uneven development, urban restructuring
and neoliberal governance. The empirical discussion is based on
studies of economic and social change, conflict and grassroots
praxis in the inner city of Dublin, Ireland, wherein a heroin crisis has
impacted for the last few decades, affecting in particular working-
class communities disadvantaged by broader patterns of economic
restructuring and urban renewal. This provides some important
analytical and political insights from a city that has undergone rapid
and intense transformation and deepening patterns of inequality
over recent decades, alongside the emergence of new forms of
urban governance and community organization and contestation. 
Epidemiological findings and medical, legal, and public health
challenges of an investigation of severe soft tissue infections
and deaths among injecting drug users – Ireland, 2000
Murray-Lillibridge K, Barry J, Reagan S, O'Flanagan D, Sayers G,
Bergin C et al. 
Epidemiology and Infection. Forthcoming article. Published Online
29 Nov 2005.
In May 2000, public health authorities in Dublin, Ireland, identified
a cluster of unexplained severe illness among injecting drug users
(IDUs). Similar clusters were also reported in Scotland and England.
Concurrent investigations were undertaken to identify the aetiology
and source of the illnesses. In Dublin, 22 IDUs were identified with
injection-site inflammation resulting in hospitalization or death;
eight (36%) died. Common clinical findings among patients with
severe systemic symptoms included leukaemoid reaction and
cardiogenic shock. Seventeen (77%) patients reported injecting
heroin intramuscularly in the 2 weeks before illness. Of 11 patients
with adequate specimens available for testing, two (18%) were
positive by 16S rDNA PCR for Clostridium novyi. Clinical and
laboratory findings suggested that histotoxic Clostridia caused a
subset of infections in these related clusters. Empiric treatment for
infections among IDUs was optimised for anaerobic organisms, and
outreach led to increased enrolment in methadone treatment in
Dublin. Many unique legal, medical, and public health challenges
were encountered during the investigation of this outbreak.
Drugs and social exclusion in ten European cities
March JC, Oviedo-Joekes E and Romero M  
European Addiction Research 2006; 12(1): 33–41
The aim of this study was to describe social characteristics seen among
socially excluded drug users in 10 cities in 9 European countries, and
to identify which social exclusion indicators (i.e. housing, employment,
education) are most closely linked to intravenous drug use. Using a
cross-sectional survey, structured interviews were held in social services
centres, town halls, streets, squares and other usual meeting points of
the target population. The sample comprised 1,879 participants who
have used heroin and/or cocaine and certain derivatives (92.3%) over
the last year. Males accounted for 69.7% of the sample, and the mean
age was 30.19 years. Participants were recruited in 10 cities: Seville,
Granada, Cologne, Vienna, Brussels, Athens, Dublin, London, Lisbon
and Perugia. 
Cannabis, heroin and cocaine are the most widely used substances.
In the total sample, 60.2% injected drugs during the last year, 45.9%
reported having hepatitis C; 54.9% have been in prison; 14.2% are
homeless; 11.3% have a regular job, and 35.2% are involved in
illegal activities. Hierarchical logistic regression analysis (injectors and
non-injectors) showed that older participants have a greater
likelihood of injecting than younger ones. Social exclusion variables
associated with intravenous drug use are incarceration, homelessness,
irregular employment, and delinquency. Participants who abandoned
or were expelled from a drug treatment program are at greater risk of
injecting drugs than participants who have never had treatment, are
currently in treatment or have been released.
The study concludes that personal, social, and economic conditions
are all linked in a process of social exclusion that compounds
problem drug misuse. Given the findings of this study, the authors
believe that there is a clear need for specific programs targeting
specific groups, i.e., distinct strategies must be set in place, in line
with the profile and needs of the patient in each context.
(Compiled by Louise Farragher and Joan Moore)
Upcoming events 
(Compiled by Louise Farragher)  Email: lfarragher@hrb.ie
March 
30 March 2006
Working with Drug Injectors 'Resistant' to Treatment 
Venue: Glasgow
Organised by / Contact: Scottish Drugs Forum
Email: enquiries@sdf.org.uk
www.sdf.org.uk 
Information: The aim of this conference will be to examine whether
various services can strengthen their responses to working with drug
injectors 'resistant' to treatment. Keynote speakers will include:
Professor Avril Taylor, University of Paisley; Dr Kennedy Roberts,
Homeless Addiction Team, Glasgow; Dr Oliver Aldridge, Harm
Reduction Team and DTTO, NHS Lothian; Dr Brian Kidd, Tayside Drug
Problem Service. 
April
5 April 2006
Drugs and Alcohol Today
Venue: Business Design Centre, Islington, London
Organised by / Contact: www.drugsandalcoholtodayexhibition.com  
Telephone: +44 (0)1273 623222
Email: info@pavpub.com 
www.drugsandalcoholtodayexhibition.com  
Information: Drugs and Alcohol Today is an event that brings
representatives from all tiers of the drugs and alcohol sector together
under one roof.  In 2006, the exhibition offers you:
■ the chance to meet representatives from 60 organisations
■ the ever-popular seminar programme, with leading policy makers,
front-line staff and service users showcasing and debating policy, best
practice and innovation.      
27–28 April 2006
11th National Conference on Management of Drug Users in
Primary Care 
Venue: Manchester International Convention Centre
Organised by / Contact: Katie Belderson, Healthcare Events
Email: katie@healthcare-events.co.uk
www.healthcare-events.co.uk 
Information: This two-day event is aimed at GPs, shared-care
workers, drug users, nurses and other primary care staff, specialists,
commissioners and researchers interested in, and involved with, the
management of drug users in primary care. 
30 April–4 May 2006
17th International conference on the reduction of drug-related
harm. Hear + Now: The Peer Conference
Venue: Vancouver, Canada
Organised by / Contact: Conference Management Team
Tel: +1 604 688 9655 ext 2
Fax: +1 604 685 3521
www.harmreduction2006.ca
Information: The ‘Hear’ in this year’s conference theme highlights
our determination to support the ‘global dialogue’ around harm
reduction. The ‘Now’ emphasizes our need to act on what we learn
drugnet
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Drugnet Ireland mailing list
If you wish to have your name
included on the mailing list for
future issues of Drugnet Ireland,
please send your contact details to
the Charlene Lydon, Drug Misuse
Research Division, Health Research
Board, Knockmaun House, 42–47
Lower Mount Street, Dublin 2. Tel:
01 676 1176 ext 127; Email:
dmrd@hrb.ie
Please indicate whether you would
also like to be included on the
mailing list for Drugnet Europe and
Drugs in focus.
The documents referred to in this
issue of Drugnet Ireland are
available in the National
Documentation Centre on 
Drug Use at the above address. 
Tel: 676 1176 ext 175; Email
ndc@hrb.ie
The Drug Misuse Research Division
(DMRD) of the Health Research
Board is a multi-disciplinary team of
researchers and information
specialists who provide objective,
reliable and comparable
information on the drug situation,
its consequences and responses in
Ireland. The DMRD maintains two
national drug-related surveillance
systems and is the national focal
point for the European Monitoring
Centre for Drugs and Drug
Addiction. The Division also
manages the National
Documentation Centre on Drug
Use. The DMRD disseminates
research findings, information and
news in Occasional Papers, in the
Overview series and in a quarterly
newsletter, Drugnet Ireland.
Through its activities, the DMRD
aims to inform policy and practice
in relation to drug use.
immediately. In specific terms, ‘PEER’
represents protection, empowerment, equality
and respect – the backbone of harm reduction
programs. The global sense of peer support
can and should encompass all members of the
harm reduction community including users
and former users, street workers, government
agencies, health care workers, policy makers,
law enforcement agencies, drug
manufacturers, and the business community.
May
2–5 May 2006 
Cork Drug Awareness Week
The aim of Cork Drug Awareness Week is to
raise awareness and signpost information so
that communities, families and professionals
know where to go for assistance or
information on drug and alcohol use. The
working group organising the events for the
week is made up of statutory and voluntary
groups involved in the area of drug
prevention, education or intervention. For
further information on any of the events,
contact Aoife Ni Chonchuir or Mella Magee,
Community Outreach Drug Awareness Project,
Cork City Partnership.
Tel: +353 (021) 4302310 
Fax: +353 (021) 4302081 
Email: anichonchuir@partnershipcork.ie or
mmagee@partnershipcork.ie
Tuesday, 2 May 2006
Addiction - its effects on the family
Time: 10:00 am-–2:00 pm
Venue: Silversprings Moran Hotel, Cork City. 
The target audience is parents, concerned
persons and anyone who is affected by
addiction.
Wednesday, 3 May 2006
Seminar on Alcohol
Keynote Speaker: Dr Joe Barry
Time: 10:00 am–2:00 pm
Venue: Clarion Hotel, Lapp’s Quay, Cork
Thursday, 4 May 2006 
Information Day
Venue: City Hall, Cork
Time: 10:00 am–8:00 pm
Various stands and groups will present on the
day, providing a broad range of information
on drug and alcohol services in Cork. The
launch of the CLDTF website and DVD will
take place at 4:00 pm. The target audience
includes schools, teachers, parents, etc. The
day will be informative and enjoyable, and will
include light entertainment in the form of
dance, competitions, music, DVD,
presentations and refreshments. 
Friday, 5 May 2006
Cork Communities Response to Drug and
Alcohol 
Venue: City Hall, Cork
Time: 2:00 pm–5:00 pm
11–13 May 2006
3rd UK/European Symposium on Addictive
Disorders. Careplans: creation to
completion
Venue: Grange City Hotel, London
Organised by /Contact: Addiction Recovery
Foundation 
Tel: +44(0)20 7233 5333
Email: info@ukesad.org 
www.ukesad.org 
Information: This three-day event will
incorporate 11 streams of presentations,
aimed at practitioners, commissioners and
researchers. Delegates will have the
opportunity to: address dysfunctional
behaviour at its root cause; sit in on expert
assessments of clients; and deepen their
understanding of dependency and thus the
implications for policy and programmes.
25 May 2006
Child protection – a sobering reality:
supporting children and families affected by
substance misuse
Venue: The Everglades Hotel, Derry, Northern
Ireland
Organised by / Contact: British Association of
Social Workers (BASW) and OiWillow Training
and Practice development 
Tel: Amanda or Eileen at BASW (NI) +44(0)28
9064 8873 or Glenn Hinds +44(0)776 376
4486
Information: This multidisciplinary conference,
organised by the British Association of Social
Workers (BASW) and OiWillow Training and
Practice development, represents an
opportunity for everyone involved at all stages
of the child protection process to come
together and contribute to the debate on how
best to respond to the needs of the children
and families affected by substance misuse.
September 
3–7 September 2006
What makes good practice – 49th
International Council on Alcohol and
Addictions (ICAA) Conference on
Dependencies
Venue: Edinburgh
Organised by / Contact: www.icaa-uk.org 
Information: The conference will provide a
broad platform of dialogue and enlightenment
for professionals in the fields of substance-
abuse prevention, treatment, research and
policymaking. 
